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Abbreviations 
5-FU 5-fluorouracile 
ADM acinar-ductal metaplasia 
AJCC american joint commission on cancer 
BCA bicinchoninic acid 
BRCA2 breast cancer type 2 susceptibility protein 
BSA bovine serum albumin 
CGH comparative genomic hybridization 
CK cytokeratin 
CT computer tomography 
DD death domain 
ECM extracellular matrix 
EMT epithelial-mesenchymal transition 
ERK extracellular regulated protein kinases 
FCM flow cytometry 
FCS fetal calf serum 
HAS heat-stable antigen 
HCAM homing cell adhesion molecule 
HER-2 human epidermal growth factor receptor 2 
HGF hepatocyte growth factor 
HUVEC human umbilical vein endothelial  
IAP inhibitor of apoptosis protein 
IC50 half maximal inhibitory concentration 
IGF1R insulin-like growth factor 1 receptor 
JAK2 janus kinase 2 
LAR luciferase assay reagent  
LPS lipopolysaccharide 
miRNA microRNA 
mRNA messenger RNA 
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PanIN pancreatic intraepithelial neoplasia 
PBS Phosphate Buffered Saline 
PDAC pancreatic ductal adenocarcinoma 
PI3K phosphoinositide-3 kinase 
PET positron emission tomography 
qRT-PCR quantitative reverse transcription real-time polymerase chain reaction 
SEER surveillance, epidemiology, and end results 
TGF transforming growth factor 
TNF tumor necrosis factor 
TRAIL tumor necrosis factor-related apoptosis-inducing ligand 
TRAIL-R1 TRAIL-receptor 1 
TRAIL-R2 TRAIL-receptor 2 
TSG tumor suppressor gene 
UICC international union against cancer 
VEGF vascular endothelial growth factor 
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1. Introduction 
1.1  Pancreatic ductal adenocarcinoma  
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It 
is one of the most lethal human cancers and leads to an estimated number of 227,000 deaths 
per year worldwide (Raimondi et al., 2009). It has a high metastatic potential and the majority 
of diseases present themselves at a very late stage. As for other cancers, the ‘TNM’ system 
has been used to stage PDAC according to the American Joint Commission on Cancer 
(AJCC) and International Union against Cancer (UICC). 'TNM' stands for Tumor, Node, and 
Metastasis. This system describes the size of a primary tumor, whether lymph nodes are 
involved by cancer cells or not, whether cancer has spread or not. There are 5 stages in the 
current TNM classification (Table 1) (http://www.cancerstaging.org/staging/posters). 
Table 1 AJCC 7th Edition TNM Staging System for Pancreatic Cancer 
Pancreas 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Limited to pancreas ≤ 2 cm 
T2 Limited to pancreas > 2 cm 
T3 Beyond pancreas 
T4 Celiac axis or superior mesenteric artery 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
Stage grouping     
Stage 0 Tis N0 M0 Localized within pancreas 
Stage IA T1 N0 M0 Localized within pancreas 
Stage IB T2 N0 M0 Localized within pancreas 
Stage IIA T3 N0 M0 Locally invasive, resectable 
Stage IIB T1,2 or 3 N1 M0 Locally invasive, resectable 
Stage III T4 Any N M0 Locally advanced, unresectable 
Stage IV Any T Any N M1 Distant metastasis 
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The median survival of PDAC is less than 6 months (Xu et al., 2011a). Surgical intervention is 
possible in about 10% of cases. Despite recent progress in chemotherapy, radiation therapy, 
and surgical resections, the overall survival rate of pancreatic cancer is still less than 5%. 
Around 95% of patients diagnosed with PDAC will die of this disease within 5 years, 3/4 
within a year (Raimondi et al., 2009).  
Pancreatic intraepithelial neoplasia (PanIN) is the presumed precursor lesion to infiltrating 
PDAC. PanINs are defined as epithelial neoplasms in the smaller pancreatic ducts (usually < 
5 mm in diameter) and can be divided into 3 grades based on the degree of architectural and 
nuclear atypical present (Hruban et al., 2001). The importance of these lesions as precursors 
to invasive PDAC has been paid great attention to during recent years because it should be 
possible to detect and treat these non-invasive precursor lesions before an incurable invasive 
cancer develops. The progression from the precursor lesions (e.g. PanIN) to PDAC suggests 
the pancreatic duct to be the origin of tumor. A more recent study provided evidence that 
PDAC might also develop in the centroacinaracinar region, through a process of acinar-ductal 
metaplasia (ADM) (Aichler et al., 2012). Therefore, study of novel biomarkers with high 
sensitivity and specificity for early detection of precursors (e.g. PanIN or ADM) is giving hope 
for improving patient survival.    
PanINs are associated with multiple genetic alterations, such as activating point mutations in 
K-ras oncogene and over-expression of human epidermal growth factor receptor 2 
(HER-2)/neu during early stage, and inactivation of the p16 tumor suppressor gene at a later 
stage followed by the loss of p53, SMAD4, and breast cancer type 2 susceptibility protein 
(BRCA2) tumor suppressor genes (Harada et al., 2007; Legoffic et al., 2009). However, 
despite a wealth of molecular studies (Koliopanos et al., 2008), none of the proposed 
biomarkers are currently recommended for clinical use. 
 
1.2  Pancreatic cancer and miRNA 
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MicroRNA (miRNA) are non-coding small RNAs, suppressing gene expression or inhibiting 
translation via binding complementary sequences in the 3'UTR of messenger RNA (mRNA)s. 
miRNAs regulate biological processes including cell proliferation, differentiation, apoptosis, 
development, metabolism and neoplastic transformation (Huang et al., 2011). It has been 
reported that the expression pattern of miRNAs rather than mRNAs are surprisingly 
informative, highly accurate in reflecting the developmental lineage and differentiation state of 
tumors (Lu et al., 2005). Comparing with other potential biomarkers, miRNA can be found 
stabilized in body fluids and tissue samples, which makes it one of the most promising ways 
for earlier detection of cancer.  
Several studies have focused on the impact of the miRNA expression pattern in PDAC and 
have shown the potential clinic value in the screening, diagnosis and prognostic prediction of 
disease using specific miRNAs, such as miR-21, miR-10b, miR-196a, and miR-221 (Basu et 
al., 2011; Bloomston et al., 2007; Giovannetti et al., 2010; Jamieson et al., 2012; Nakata et al., 
2011; Szafranska et al., 2007). Most recently, the miRNA alterations that arise during the 
development of PanINs has also been identified (Yu et al., 2012). In the future, miRNA 
expression pattern in PanINs or PDAC may serve as a novel screening tool and potent 
monitor in PDAC progression. Equally as exciting, it is very promising to research for novel 
therapies directed against these important disease mediators.  
 
1.3  Pancreatic head cancer and body/tail cancer  
1.3.1 Difference in anatomy and embryology  
PDAC can be divided into head and body/tail cancers according to the anatomy. Distinctions 
in anatomical conditions are well known from embryology (In't Veld et al., 2010), 
histopathology (Atri et al., 1994; Zyromski et al., 2009), and imaging findings (Kawamoto et 
al., 2009; Schoennagel et al.; Wiersema et al., 1995; Yoshikawa et al., 2006). 
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Pancreatic development begins with the formation of ventral and dorsal buds, which becomes 
a ventral head (lower head and uncinate process) and dorsal pancreas (upper head, body 
and tail), respectively (Figure 1).  
 
Figure 1. The development of the pancreas from dorsal and ventral buds. 1: Head of pancreas; 2: 
Uncinate process of pancreas; 3: Pancreatic notch; 4: Body of pancreas; 5: Anterior surface of 
pancreas; 6: Inferior surface of pancreas; 7: Superior margin of pancreas; 8: Anterior margin of 
pancreas; 9: Inferior margin of pancreas; (From Wikipedia: http://en.wikipedia.org/wiki/Main_Page) 
This difference in ontogeny leads to significant differences in cell composition, blood supply 
and innervations between the head and body/tail of pancreas (In't Veld et al., 2010). The 
superior pancreaticoduodenal artery (a branch of the gastroduodenal artery) and the inferior 
pancreaticoduodenal artery (a branch of the superior mesenteric artery) run in the groove 
between pancreas and duodenum and supply the head of pancreas. While the pancreatic 
branches of splenic artery supply the neck, body and tail of pancreas. The head of pancreas 
drains into the superior mesenteric and portal veins, while the body and neck drain into 
splenic vein (Figure 2).  
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Figure 2. The blood supply and venous drainage of pancreas. (From EndocrineSugeon: 
http://www.endocrinesurgeon.co.uk) 
Pancreas is both an endocrine gland producing important hormones (e.g. insulin, glucagon, 
somatostatin, and pancreatic polypeptide) and a digestive organ secreting pancreatic juice, 
which assist the intestinal absorption of nutrients. The endocrine part of the pancreas is made 
up of approximately one million cell clusters called islets of Langerhans. The endocrine cells 
have different secretary functions: α cells secrete glucagon (increase glucose in blood), β 
cells secrete insulin (decrease glucose in blood), δ cells secrete somatostatin 
(regulates/stops α and β cells), and pancreatic polypeptide cells secrete pancreatic 
polypeptide. The endocrine cells (α-, β-, δ- and pancreatic polypeptide cells) are remarkably 
differentially distributed between head and body/tail of pancreas (In't Veld et al., 2010). The 
number of endocrine (Langerhans) islets is greater in the body and tail. Insulin-positive 
endocrine cells are highly refractory to malignant transformation under normal conditions, but 
a recent study has found that insulin-positive endocrine cells could serve as a cell-of-origin of 
PDAC under oncogenic mutation inducement in combination with pancreatic injury (Gidekel 
Friedlander et al., 2009).  
In addition, the distinction between pancreas head, body, and tail regions is also reflected by 
different appearances in ultrasonography (Wiersema et al., 1995), computer tomography 
(Kawamoto et al., 2009), and magnetic resonance imaging (Yoshikawa et al., 2006). Studies 
have shown that fatty infiltration is usually most prominent in the anterior aspect of the 
pancreas head and may stimulate pancreatic neoplasm (Hori et al., 2011; Kawamoto et al., 
2009; Zyromski et al., 2009). In this sense, pancreatic head and body/tail cancers may have 
different malignant potential. 
 
1.3.2 Difference in clinical presentation 
Although increasing evidence has shown differences on clinical presentation (incidence, 
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symptoms, resectability) between pancreatic head and body/tail cancers (Bilimoria et al., 
2007; Lau et al., 2010; Matsuno et al., 2004; van Oost et al., 2006), the molecular diversity 
between the two subtypes of PDAC has not been clarified so far.  
1.3.2.1  Incidence  
Data from Surveillance, Epidemiology, and End Results (SEER) registries of Unite States 
(1973-2002) have shown that about 77.5% (34,072/43,946) of pancreatic cancer originate at 
the head of the pancreas, on which consequently most discussion on pancreatic cancer has 
been focused (Lau et al., 2010). The overall annual incidence of pancreatic head cancer is 
5.6 per 100,000, compared with 1.6 of pancreatic body/tail cancer (Lau et al., 2010). Data 
from National Pancreatic Cancer Registry of Japan (1981-2002, n = 9290) (Matsuno et al., 
2004) and Eindhoven Cancer Registry of Netherland (1995-2000, n = 1128) (van Oost et al., 
2006) also demonstrated much higher incidences of pancreatic head cancer (62.3% and 
56.5%, respectively) than body/tail cancer (17.5% and 12.7%, respectively). For resectable 
tumors (Stage I: T1N0M0 and T2N0M0), about 70% (6676/9559) located in the head of 
pancreas as shown by another database in the Unite States (National Cancer Data Base, 
1995-2004) (Bilimoria et al., 2007). 
1.3.2.2  Symptoms 
Symptoms often do not appear until the disease is at an advanced stage, thus making early 
detection difficult. Notably, a patient's symptoms will vary depending on the location of the 
cancer within the pancreas. Both pancreatic head and body/tail cancers can cause 
non-specific symptoms, such as abdominal pain, nausea, loss of appetite and weight loss. 
However, only tumor blocking the bile ducts, which pass through the head of pancreas, can 
cause jaundice (Figure 3). A study from China investigated the clinical-pathological 
characteristics between pancreatic head cancer (n = 541) and body/tail caner (n = 106) from 
1980 to 2003. They found that patients primarily diagnosed with pancreatic body/tail cancer 
were associated with much less jaundice but more pain, higher serum albumin level, higher 
carcinoembryonic antigen but lower carbohydrate antigen 19-9 positive rates, and higher 
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metastasis rate (Wu et al., 2007). Other studies also confirmed that patients with pancreatic 
body/tail cancer were more likely to be diagnosed at an advanced stage (Eyigor et al., 2010; 
Sener et al., 1999). SEER registries database reported that patients with pancreatic body/tail 
cancer had a higher proportion of the distant stage diseases (72.7% vs. 39.2%) compared 
with patients with pancreatic head cancer (Lau et al., 2010).  
(A)  (B)  
Figure 3. Pancreatic cancer located in the head (A) and body/tail (B) of pancreas. Bile duct passes 
through the head of pancreas. Therefore, pancreatic head cancer can easily block the bile ducts and 
cause jaundice. (A from Doctor Tipster: http://www.doctortipster.com; B from CPMC Sutter Health: 
http://www.cpmc.org/index.cfm) 
 
1.3.2.3  Diagnostic characterization of genetic markers 
Biomarkers are important to the early diagnosis and prompt treatment of diseases. 
Carbohydrate antigen 19-9 is a routinely used serum biomarker for PDAC (Humphris et al., 
2012). A study from China found that pancreatic body/tail cancer was associated with lower 
serum carbohydrate antigen 19-9 but higher serum carcinoembryonic antigen levels (Wu et 
al., 2007). However, there is lack of a high sensitive biomarker for PDAC, which make the 
early diagnosis difficult and lead to a dismal prognosis.  
Most recently, as a consequence of technical advances, whole sequencing of the cancer 
exome has been performed and leads to greater insight into the mutational spectrum of 
human cancers, including PDAC (Iacobuzio-Donahue, 2012; Jiao et al., 2011; Jones et al., 
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2004; Sjoblom et al., 2006). In 2008, a comprehensive genetic analysis containing 24 PDACs 
determined an average of 63 genetic alterations in the sequences of 23,219 transcripts, 
representing 20,661 protein-coding genes. A core set of 12 cellular signaling pathways and 
processes explaining the major features of pancreatic tumorigenesis have been defined by 
these alterations (Jones et al., 2008). Fifteen out of 24 PDAC samples were obtained from 
the primary tumors. However, the precise locations were not provided, a comparison between 
pancreatic head and body/tail cancers is impossible in this context. 
 
1.3.3 Difference in surgical treatment 
A pancreatectomy is the surgical removal of pancreas (part or all). Several types of 
pancreatectomy exist, such as ‘pancreaticoduodenectomy’ (Whipple procedure), ‘distal 
pancreatectomy’, ‘segmental pancreatectomy’, and ‘total pancreatectomy’. Pancreatic head 
and body/tail cancers are usually treated with ‘pancreaticoduodenectomy’ and ‘distal 
pancreatectomy’, respectively (Figure 4).   
 
Figure 4. Pancreatic head and body/tail cancers are treated with ‘pancreaticoduodenectomy’ (Whipple 
procedure) and ‘distal pancreatectomy’, respectively. (From CPMC Sutter Health: 
http://www.cpmc.org/index.cfm) 
The Whipple procedure consists of removal of the distal half of the stomach (antrectomy), the 
gall bladder and its cystic duct (cholecystectomy), the common bile duct (choledochectomy), 
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the head of the pancreas, duodenum, proximal jejunum, and regional lymph nodes. 
Reconstruction (the original one is called Child's reconstruction) consists of attaching the 
pancreas to the jejunum (pancreaticojejunostomy), attaching the hepatic duct to the jejunum 
(hepaticojejunostomy), and attaching the stomach to the jejunum (gastrojejunostomy). So 
that digestive juices and bile can flow into the gastrointestinal tract and food can also pass 
through.  
A distal pancreatectomy is the resection of pancreatic tissue to the left of the superior 
mesenteric vascular. It has been considered as the standard technique for management of 
benign and malignant pancreatic disorders in the body and tail. With the improvement of 
surgical technique, a surgical procedure is available where the spleen is preserved removing 
only the pancreas, which is also known as spleen preserving distal pancreatectomy. 
 
1.3.4 Difference in prognosis 
It is not surprising that pancreatic head cancer has a better overall patient survival than those 
with pancreatic body/tail cancer, because much more patients with pancreatic body/tail 
cancer are diagnosed at a relatively advanced stage. SEER registries database showed 
pancreatic head cancer had a 4% lower overall mortality risk compared with pancreatic 
body/tail cancer (Lau et al., 2010). However, within the same local-stage, pancreatic head 
cancer had a much lower 3-year survival rate than pancreatic body/tail (Lau et al., 2010). The 
National Cancer Data Base of Unite States (1985-1995) including information from 100,313 
patients also presented a higher 5-year survival rate for local-stage pancreatic tail cancer 
(32.4%) compared with local-stage pancreatic head cancer (11.1%) (Sener et al., 1999). 
Consistent with the results from Western countries, the study from Japan, as mentioned 
before (Matsuno et al., 2004), showed a significantly higher median survival time (10.2 vs. 9.2 
months) and 5-year survival rate (13.8% vs. 10.7%) for pancreatic body/tail cancer (n = 1629) 
than pancreatic head cancer (n = 5788) in invasive types.  
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As long as operation is possible, the pancreatic head cancer is surgically treated by 
pancreaticoduodenectomy, while pancreatic body/tail cancer is treated by a distal 
pancreatectomy. As mentioned previously, more tumors are diagnosed at early stage and the 
resectability is higher in pancreatic head cancer. Regarding the complexity of the surgical 
procedure, pancreatic body/tail cancer shows lower morbidity and mortality than pancreatic 
head cancer after surgery (Glanemann et al., 2008). 
Although surgical resection remains to be the only potential cure for PDAC, only 15-20% of 
patients newly diagnosed with PDAC are considered for surgical resection (Castellanos et al., 
2011). Chemo and/or radiotherapy have emerged as a key factor to improve patient survival 
both in resectable and non-resectable tumors (Sata et al., 2009). Reports from both Western 
countries and Japan showed that tumor site (head vs. body/tail) did not relate to progression 
free-survival or overall survival in patients with advanced or metastatic pancreatic cancer 
treated with Chemo and/or radiotherapy (Chang et al., 2009; Marechal et al., 2007; Morganti 
et al., 2003; Tanaka et al., 2008). For resectable tumors, adjuvant chemotherapy was found 
to be a significant independent predictor of a favorable prognosis in a cohort of 34 Japanese 
patients with pancreatic body/tail cancer (Murakami et al., 2009), and was thus recommend 
for patients with pancreatic head cancer (Katz et al., 2010). However, no large study has yet 
been conducted for comparing the different response to chemo and/or radiotherapy such as 
toxicity and tumor progression between different tumor sites. 
 
1.3.5 Difference in in vitro models 
Cancer cell lines recapitulate the genomic events leading to tumor changes seen in clinical 
tissues and are valuable tools in studies of tumor cell biology. Different PDAC cell lines 
arising from primary tumors, liver metastasis, ascites, or lymph node metastasis, exhibit a 
great deal of diversity in structure and function. Among PDAC cell lines originating from the 
primary tumors, Panc-1 and MIA PaCa-2, which are matched by donor age (±10 years), 
tumor stage, histological differentiation (Table 2) and ultrastructural features (Table 3) (Deer 
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et al., 2010; Sipos et al., 2003), were selected as the one representing pancreatic head 
cancer and body/tail cancer, respectively.  
 
Table 2 Clinical profile and origin of PDAC cell lines originated from primary tumor 
Cell line Age  Gender  Derivation  Stage Differentiation  Therapy  Survival  
BxPC-3 61 Female  Body  II-III  Moderate to 
poor 
Chemotherapy 
Radiotherapy 
6.75 yrs 
Capan-2 56 Male  Head  IIA  well  Surgery 
Chemotherapy 
0.5 yrs 
MIA PaCa-2 65 Male  Body/tail II-III Poor  - - 
Panc-1 56 Female  Head  IIB  Poor  Surgery - 
 
Table 3 Grading of ultrastructural features of PDAC cell lines originating from primary tumor  
Cell line Cellular 
polymor
phism 
Nuclear 
polymor
phism 
Cell 
membrane 
structures 
Mucin 
granules 
Cell 
organelles 
Lumen 
formation 
Cell 
polarity 
Final 
score 
Grade 
Monolayers a 
BxPC-3 3 2 1-2 1 1-2 - - 9 2 
Capan-2 1 2-3 2 1-2 1 - - 8 1 
MIA PaCa-2 3 2-3 3 2 3 - - 13.5 3 
Panc-1 3 3 3 3 2-3 - - 14.5 3 
Spheroids b 
BxPC-3 3 2 1 1-2 2 1-2 3 14 2 
Capan-2 1-2 2 1 1-2 1 1 1-2 9.5 1 
MIA PaCa-2 - - - - - - - 20 c 3 
Panc-1 3 3 2 2 2 2 3 17 3 
a: Grading of ultrastructural features of monolayer cultures of PDAC cell lines (grade 1 score 5-8, grade 
2 score 9-12, grade 3 score 13-15) 
b: Grading of ultrastructural features of spheroid cultures of PDAC cell lines (grade 1 score 7-11, grade 
2 score 12-16, grade 3 score 17-21) 
c: Estimated score because no spheroid formation. 
Compared to MIA PaCa-2, Panc-1 showed a higher binding affinity to collagens (type I and 
IV), the most abundant protein in the extracellular matrix (ECM), and exhibited higher 
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adhesion ability to endothelial cells (Deer et al., 2010; ten Kate et al., 2006). In addition, 
Panc-1 expressed greater levels of a series of cell adhesion molecules (ten Kate et al., 2006). 
A study using co-culture system with PDAC cells and tumor-derived fibroblasts demonstrated 
that hepatocyte growth factor produced by the fibroblasts could initiate an apparent 
invasion-stimulating response in strong c-met expressing Panc-1 cells but not in weak 
expressing MIA PaCa-2 cells (Qian et al., 2003). 
Panc-1 exhibited much higher half-maximal inhibitory concentration (IC50) values for 
5-fluorouracile (5-FU) and Gemcitabine, and higher irradiation dose than MIA PaCa-2 (Dai et 
al., 2010; Galloway et al., 2009; Pan et al., 2008). The possible reason was that the 
expressions of anti-apoptotic proteins were much higher in Panc-1 than those in MIA PaCa-2 
(Galloway et al., 2009; Pan et al., 2008).  
Both Panc-1 and MIA PaCa-2 presented high intra-pancreatic tumorigenicity, local infiltration 
and distant metastasis potential in an orthotopic injection of cancer cell model, which could 
better reflect the clinical microenvironment and provide more convincing data compared to 
other methods (Hotz et al., 2003; Loukopoulos et al., 2004). However, data directly 
comparing the tumorigenicity of the two PDAC cell lines were not given in this model. By 
using immunohistochemical analysis in vivo, Panc-1 and MIA PaCa-2 tumors demonstrated 
quite similar major morphology, mucin accumulation, cytokeratin (CK) profile (CK7/CK19 and 
CK8/CK18), trans- (Vimentin, CK20, Chr-A and α1-chym) and dedifferentiation (pdx-1, shh 
and ptc) patterns (Neureiter et al., 2005). 
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1.4  Aim of the study 
So far, not enough attention has been paid to the molecular diversity between pancreatic 
head and body/tail cancers and the overall information is limited. The current clinical data 
support higher incidence and easier detection of pancreatic head cancer compared with 
pancreatic body/tail cancer. For tumors at the local-stage, pancreatic head cancer has a 
lower survival than pancreatic body/tail cancer. Although the previous reports describe large 
cohort of patients, the evidence is still not convincing because there is a lack of strictly 
case-matched comparison between the two subtypes of PDAC. Further pioneering studies on 
patient tumor samples are needed. 
It is likely that the majority of human genes are regulated by miRNAs. The discovery of 
miRNAs offers a new opportunity to uncover the aberrantly expressing cellular pathways 
during the pathognomonic carcinogenetic events for all human cancers.  
Our aim was to evaluate the genetic diversity at molecular level between the pancreatic head 
cancer and pancreatic body/tail cancer. We performed a comparison of miRNA expression 
profile between pancreatic body/tail cancer and pancreatic head cancer, and found two 
miRNAs were significantly differentially expressed. We further aim to clarify the role of the 
differentially expressed miRNA in the phenotype varity between pancreatic body/tail cancer 
and pancreatic head cancer in vitro study. 
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2. Materials and methods 
2.1  Tissue samples and cell sources 
Patients with newly diagnosed early stage (I-II) PDAC were considered eligible for this study. 
Informed written consent was obtained from each patient. Research protocol was approved 
by the ethical committee of the First Affiliated Hospital, Zhejiang University and strictly 
followed the guidelines of the Ethical Committee of this hospital and the Declaration of 
Helsinki. Tumor samples were obtained directly from surgery. The Whipple procedure and 
distal pancreatectomy was performed for pancreatic head cancer and body/tail cancer, 
respectively, by the same surgery group, led by Prof. Shusen Zheng. Hematoxylin and Eosin 
stained tissue sections were reviewed by two independent surgical pathologists. All tumors 
were classified according to the TNM staging system. 
PDAC cell lines (Capan-1, Capan-2, Panc-1, PancII-1, Panc89, BxPc-3 and Colo357) are 
derived from the Institute for Experimental Cancer Research, UKSH, Campus Kiel, Germany, 
if not otherwise stated. The detailed information has been given in our precious report (Sipos 
et al., 2003). 
 22
2.2  Materials 
2.2.1 Instruments 
Description Type  Company  
Agilent Bioanalyzer  2100 Agilent technologies Inc., USA 
Agilent Microarray Scanner G2565BA Agilent technologies Inc., USA 
Blotting chamber Mini Trans Blot Cell Bio-Rad Laboratoeries GmbH, 
München 
Branson Sonifier PG. 1029 MSE, UK 
Cell culture centrifuge Rotina 48 R Hettich, Tuttlingen 
Cellometer Auto  T4 Nexcelom Bioscience LLC, USA 
Centrifuge  Mini Spin Plus Eppendorf, Hamburg  
ECL- chemiluminescence-film  Hyperfilm GE Healthcare Europe GmbH, 
München 
Film developer Curix60 Agfa, Gera 
Flow cytometry system BD FACSCaliburTM BD Biosciences, USA 
Heidolph duoMax-Rotator shake 1030 Heidolph Instruments GmbH, 
Schwabach 
Heraeus quartz heaters 6000 Heraeus Instruments, Hanau 
Hybridization Chamber  G2534A Agilent technologies Inc., USA 
Hybridization oven  G2545A Agilent technologies Inc., USA 
Hybridization oven rotator  G2530-60029 Agilent technologies Inc., USA 
Magnetic stirrers MR300T Heidolph Instruments GmbH, 
Schwabach 
Microcentrifuge 5417R  Eppendorf, Hamburg 
Microscope  Axiovert 135 Carl Zeiss AG, Oberkochen 
Minicentrifuge  GalaxiMini  VWR, Darmstadt 
Opaque glasses Diameter 18 mm Th. Geyer, Renningen 
Photometer  Sunrise  Tecan Trading AG, Schweiz 
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Real-time PCR system 7700HT Applied Biosystems, Darmstadt 
Roll-mixer Assistant RM5 Assistant, Sondheim 
Standard Power Pack P25 Biometra GmbH, Goettingen 
Thermoblock  Thermomixer 
compact 
Eppendorf, Hamburg  
Vortex  Vortex Genie2 Scientific industries Inc., USA 
Water bath WBT12 Reiss-Daimler Medingen 
Water Purification System Milli-Q Millipore GmbH, Schwalbach 
Water-jacketed incubator 3250 Thermo Scientific Forma, UK 
 
2.2.2 Consumables 
Description Company  
Cell culture plates (6-, 24-, 96-well) Sarstedt, Nümbrecht 
Cell culture flasks (25 cm2 and 75cm2) Sarstedt, Nümbrecht 
Cell scraper (16 cm) Sarstedt, Nümbrecht 
Chromatography paper (3 mm) Whatman GmbH, Dassel 
Cryovials  Nalgene, Rochester 
Falcons (15ml and 50ml) Sarstedt, Nümbrecht 
Novex® Tris-Glycine gels Invitrogen, Karlsruhe 
Pipette tips Eppendorf, Hamburg 
Pipettes (10 μl, 20 μl, 100 μl, 200μl and 1 ml) Eppendorf, Hamburg  
Powder-free gloves GE Healthcare Europe GmbH, München 
PVDF-transfer membrane Millipore GmbH, Schwalbach 
Serological Pipettes (5 ml, 10 ml, and 25 ml ) Sarstedt, Nümbrecht 
ThinCerts™ Cell Culture Inserts (8 μm) Greiner Bio-One, Frickenhausen 
Tubes (1.5ml and 2ml)  Eppendorf, Hamburg  
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2.2.3 Buffers 
Description Composition   
Crystal violet (0.5%) 5 ml crystal violet (5%); 5 ml Methanol (100%); adjust to 50 ml 
aqua dest 
Running buffer 10 × 30.3 g (0.25 M) Tris Base; 144 g (1.92 M) Glycine; 10 g (1%) 
SDS; 1000 ml ddH2O; Dilute 1:10 with ddH2O; PH will be 8.3 
Transfer buffer 10 × 288 g glycine; 60.4 g Tris base; 200 ml Methanol; 1.8 L ddH2O 
TBST 10 × 400 g NaCl; 121 g TrisBase; Add aqua dest to a volume of 4 l 
(about 20 min); Adjust the pH to pH 7.6 (~100ml HCl (25%)); 
Add 50ml Tween; Add aqua dest to a final volume of 5 l 
 
2.2.4 Chemicals and media 
Description Company  
Accutase  PAA Laboratories GmbH, Cölbe 
Amersham ECL Plus Western blotting 
Detection Reagents 
GE Healthcare Europe GmbH, München 
Amersham ECL Western blotting Detection 
Reagents 
GE Healthcare Europe GmbH, München 
Aqua for injection  B. Braun Melsungen AG, Melsungen 
Bovine serum albumin (BSA) Sigma-Aldrich Chemie GmbH, München 
Complete Mini Protease-Inhibitor Cocktail  Roche Diagnostic GmbH, Mannheim 
Collagen I (rat tail) Roche Diagnostics, GmbH, Mannheim 
Crystal violet   Sigma-Aldrich Chemie GmbH, München 
Curix 60 Developer G153 A and B Agfa, Gera 
Curix 60 Rapid Fixer G354 Agfa, Gera 
DharmaFECT 1 siRNA Tansfection Reagent Thermo Fisher Scientific, Bonn 
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D-Phosphate Buffered Saline (PBS) Invitrogen, Karlsruhe 
Fetal calf serum (FCS) Sigma-Aldrich Chemie GmbH, München 
Glutamine Invitrogen, Karlsruhe 
Glyceraldehydes  Sigma-Aldrich Chemie GmbH, München 
Glycine  Carl Roch GmbH & Co. KG, Karsruhe 
Isopropanol  Otto Fischar GmbH, Saarbrücken 
KCl Merck KGaA, Darmstadt 
lipopolysaccharide (LPS) Sigma-Aldrich Chemie GmbH, München 
Methanol   Carl Roch GmbH & Co. KG, Karsruhe 
mirVana™ miR-501-3p inhibitor Applied Biosystems, Darmstadt  
mirVana™ miR-501-3p mimic Applied Biosystems, Darmstadt  
mirVana™ miRNA inhibitor negative control Applied Biosystems, Darmstadt  
mirVana™ miRNA mimic negative control Applied Biosystems, Darmstadt  
NaCl J.T. Baker, Niederlande  
NaOH Merck KGaA, Darmstadt 
Nonfat dried milk power AppliChem, Darmstadt 
Opti MEM culture medium Invitrogen, Karlsruhe 
PhosSTOP Phosphatase Inhibitor Cocktail Roche Diagnostic GmbH, Mannheim 
Power SYBR Green Master Mix Applied Biosystems, Foster City 
Random Primer New England Biolabs, Frankfurt am Main 
RPMI, GlutaMAX™ Invitrogen, Karlsruhe 
Spectra Multicolor Broad Range Protein Ladder Fermentas GmbH; St: Leon-Rot 
SYBR Green Master Mix Qiagen, Hilden 
Tris base Merck KGaA, Darmstadt 
Trypsin 10 × Sigma-Aldrich Chemie GmbH, München 
Tween  Merck KGaA, Darmstadt 
 
2.2.5 Kits 
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Kits  Company  
Dual luciferase® reporter assay kit  Promega, USA 
Gene Expression Wash Buffer Kit Agilent technologies Inc., USA 
Human miRNA Microarray Kit version 14.0 Agilent technologies Inc., USA 
MicroRNA Spike-In Kit Agilent technologies Inc., USA 
miRNA Complete Labeling and Hyb Kit Agilent technologies Inc., USA 
mirVana™ miRNA Isolation Kit Ambion, USA 
miScript Reverse Transcription Kit Qiagen, Hilden  
Pierce BCA Protein Assay Kit Thermo Fisher Scientific, Bonn 
RNA 6000 Nano Kit Agilent technologies Inc., USA 
RNA 6000 Pico Kit  Agilent technologies Inc., USA 
RT-for-PCR kit Clontech Laboratories, Inc., USA 
 
2.2.6 Hardware and software 
Description 
ABI Prism 7700 SDS software (Applied Biosystems) 
Adobe Acrobat Reader 4.0 (Adobe Systems Inc.) 
Adobe Photoshop CS3 (Adobe Systems Inc.) 
Agilent G4450AA Feature Extraction software 9.5 (Agilent technologies Inc.) 
Agilent Gene Spring Software 11.0 (Agilent technologies Inc.) 
Agilent GeneSpring software GX10.0 (Agilent technologies Inc.) 
Agilent Scan Control software, version A. 7.0 (Agilent technologies Inc.) 
Microsoft Internet Explorer 5.5 
Microsoft Windows 2000 with SP2 (fully tested on SP4), Windows XP SP2 
Pentium IV 1.5 GHz  
SBC analysis system (ShanghaiBio Corp.) 
SDS 2.1 software (Applied Biosystems) 
SPSS windows 13.0 (SPSS Inc.) 
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60 GB available disk space  
1 GB RAM  
 
2.2.7 Antibodies  
Antibody  Source   Dilution  Company  Cata No. 
Anti-human Caspase-8 Mouse 1:1000 Cell Signaling, Frankfurt 9746 
Anti human E-Cadherin Mouse 1:2500 R&D systems, Wiesbaden 610181 
Anti human VE-Cadherin Rabbit 1:1000 Cell Signaling, Frankfurt 2158s 
Anti human TRAIL R1 Rabbit 1:1000 Milipore GmbH, 
Schwalbach  
16955 
Anti human TRAIL R2 Rabbit 1:4000 ProSci Inc., Lörrach 2019 
Anti β-actin mouse 1:50,000 Sigma-Aldrich Chemie 
GmbH, München 
A5441 
Anti mouse IgG Goat 1:3000 Cell Signaling, Frankfurt 7076 
Anti rabbit IgG Goat  1:3000 Cell Signaling, Frankfurt 7074 
Anti goat IgG Ape  1:3000 Santa Cruz Biotechnology, 
Heidelberg 
sc-2304 
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2.3  Methods 
2.3.1 RNA Isolation 
Total RNA was extracted and purified using mirVana™ miRNA Isolation Kit following the 
manufacturer’s instructions. Small pieces of tissues were quickly cut and weighed. 
Lysis/Binding Buffer (10 volumes of per tissue mass), miRNA Homogenate Additive (1/10 
volume) and Acid-Phenol:Chloroform were added into the powdered tissue sample and 
mixed well. The mixture was centrifuged for 5 min at maximum speed at room temperature. 
Aqueous (upper) phase was then carefully transferred into a fresh tube, mixed with 1.25 
volumes of 100% ethanol, transferred into a Filter Cartridge and centrifuged for 15 sec. 
miRNA Wash Solution 1 (700 μl) was added into the Filter Cartridge and centrifuged for 5-10 
sec. After discarding the flow-through, miRNA wash Solution 2/3 (500 μl) was added and 
drawn through the Filter Cartridge twice. After discarding the flow-through from the last wash, 
the Filter Cartridge was transferred into a fresh collection tube. Pre-heated (95°C) 
nuclease-free water (100 μl) was used to recover the RNA.  
2.3.2 MicroRNA Microarray 
Microarray analysis was performed by SHANGHAI BIOTECHNOLOGY CORPERATION 
(www.ebioservice.com) using the Agilent Human miRNA Microarray Kit (8×15k) version 14.0 
(design ID: 31945). miRNA molecular in total RNA was labeled by miRNA Complete Labeling 
and Hyb Kit. Each slide was hybridized with 100ng Cy3-labeled RNA using miRNA Complete 
Labeling and Hyb Kit in hybridization Oven at 55°C, 20rpm for 20 hours. After hybridization, 
slides were washed in staining dishes with Gene Expression Wash Buffer Kit. Slides were 
scanned by Agilent Microarray Scanner and Feature Extraction software. Raw data were 
normalized by Quantile algorithm, Gene Spring Software 11.0. The data were analyzed by 
SBC analysis system (ShanghaiBio Corp.) 
(http://www.ebioservice.com/show_product.asp?id=398). 
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2.3.3 Reverse Transcription and Real-time PCR 
Reverse transcription and Real-time PCR was performed by Zhikun Liu (The First Affiliated 
Hospital, Zhejiang University, Hangzhou, China) using the Advantage RT-for-PCR kit in the 
7700 HT real-time PCR System. All reactions were measured in triplicates in a final volume of 
25 μl: 12.5 μl SYBR Green Mix (2 ×), 0.2 μl cDNA, 1 μl primer pair mix (5 pmol/μl per primer), 
and 11.3 μl ddH2O. Cycling conditions were chosen according to the manufacturer’s protocols. 
Briefly, real-time PCR started with the incubation of samples at 50°C for 2 min followed by 
95°C for 10 min. Following this, quantitative PCR was repeated for 40 cycles with incubation 
at 95°C for 15 s followed by at 60°C for 1 min. The cycle number at which the real-time PCR 
reaction reached an arbitrarily determined threshold (CT) was recorded for both the 
miRNAs/RNAs and U6/GAPDH, and the relative amount of miRNA to U6 was described as 2 
-ΔΔCT where ΔCT x = (CTmiRNA x - CTU6 x) and ΔΔCT x= (ΔCT x - ΔCT mean). 
2.3.4 Cell Lysate Extracts 
The 6-well plate was put on ice and washed with ice-cold PBS. Ice-cold modified RIPA buffer 
(supplemented with Phosphatase inhibitor Cocktail tablet and Protease Inhibitor Cocktail 
tablet) was used for lysation. After 10 min incubation on ice and 20 min on -80°C, lysed cells 
were transferred into an eppendorf tube. The cell lysate was then lysed with ultrasound and 
centrifuged at 14,000 × g for 15 min. The supernatant was immediately transferred into a 
fresh centrifuge tube. 
2.3.5 Pierce Assay 
Protein concentration was tested using Pierce BCA Protein Assay Kit according to the 
standard protocol. Working reagent was prepared by mixing 50 parts of Pierce BCA 
(bicinchoninic acid) Reagent A with 1 part of BCA Reagent B (50:1, Reagent A:B). From each 
protein sample, 20 μl was pipetted triply into a 96-well plate. 200 μl working reagent was then 
added into each well and incubated at 37°C for 30 min. The absorbance was measured at 
near 562 nm. The concentration was calculated using a standard curve. 
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2.3.6  Western Blot 
The extract (10 or 20 μg) was electrophoresed on Novex® Tris-Glycine gels at 125 V for 120 
min and electroblotted onto PVDF-transfer membrane at 400 mA for 70 min. The blots were 
blocked with 5% nonfat milk or BSA in TBST washing buffer for 2 h at room temperature and 
then incubated at 4 °C overnight with primary antibodies. All antibodies were diluted 
according to the manufacturer’s instructions. After washed at room temperature with washing 
buffer, the blots were labeled with secondary antibodies for 1 hour at room temperature. Then 
the blot was washed, incubated with ECL for 1 min, and exposed for 1-5 min in the film 
developer. 
2.3.7 Crystal Violet Assay 
After removal of the old medium, cells were incubated with 50 μl of 0.5% crystal violet solution 
per well at room temperature on a shaker. After 20 min, cells were washed at least 5-6 times 
with 200 μl water per well and dried at room temperature over night. Then cells were 
incubated with 200 μl methanol per well for 20 min on the shaker at room temperature and 
measured at 590 nm. 
2.3.8 SiRNA Transfection 
In separate tubes, the siRNA (Tube 1: 44 μl of 5 μM siRNA, 66 μl RNase-free water, 110 μl 
OptiMEM) and DharmaFECT1 transfection reagent (Tube 2: 3.85 μl of DharmaFECT 1, 
216.15 μl OptiMEM) were diluted with OptiMEM. The contents of each tube were mixed 
gently by pipetting carefully up and down, and incubate for 5 min at room temperature. 
Contents of Tube 1 was then added into Tube 2, mixed and incubated for 20 min at room 
temperature. For 6-well plate, 400 μl of the transfection mix was added to each well. Cells 
were incubated at 37ºC in 5% CO2 for 72 hours. 
2.3.9 Invasion Assay 
PDAC cells were harvested and resuspended in 0.5% FCS to a final concentration of 1 × 
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105/ml. In a Collagen I (50μl at 0.4 mg/ml)-coated transwell chambers, 5 × 104 cells were put 
into upper chamber and 750 μl of 10 % FCS was put into lower chamber. After 24 hours 
culture at 37°C and 5 % CO2, cells that did not migrate through the pores and therefore 
remained on the upper chamber were gently removed with a cotton swab. Crystal Violet 
(0.1%) was used to stain the cells and acetic acid (10%) was used to solubilize. Cell numbers 
were quantified by measuring the intensity of the colored solution using a photometer at 590 
nm. The intensity of the untreated transwell was set to 100% as control.  
2.3.10 Dual Luciferase Activity Assay  
Dual Luciferase Activity Assay was performed by Zhikun Liu (The First Affiliated Hospital, 
Zhejiang University, Hangzhou, China), and technically supported by SHANGHAI 
GENEPHARMA CORPERATION (www.genepharma.com). Double-stranded oligonucleotides 
corresponding to the wild-type (WT-3’UTR) or mutant (MUT-3’UTR) miR-501-3p binding site 
in the CDH5 3’UTR were synthesized and ligated into the psiCHECKTM-2 Vector. HUVEC 
cells were cultured in 6-well plates and transfected with WT-3’UTR or MUT-3’UTR and 
cotransfected with miR-501-3p mimics/inhibitors or negative controls. Firefly and Renilla 
luciferase activities were measured by using dual luciferase reporter assay kit 48 h after 
transfection. Firefly luciferase activity was normalized to Renilla luciferase activity. 
2.3.11 Statistical analysis 
Statistical analyses were performed using windows for SPSS 13.0 and SBC analysis system. 
P < 0.05 was considered to be statistically significant. The Kolmogorov-Smirnov test was 
used to check for normality. Quantitative variables were expressed as mean ± SD or median. 
Categorical variables were presented as values and percentages. Paired-sample t test, 
Wilcoxon-Man-Whitney test and chi-square test (Fisher’s exact test) were used to compare 
quantitative and categorical variables, respectively. The Kaplan-Meier method and log-rank 
test were used for survival comparison. Cox regression analysis was used to determine the 
risk factors of tumor recurrence after curative surgical resection. 
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3. Results 
3.1  Differentially expressed miRNAs between pancreatic head and 
body/tail cancers  
3.1.1 Different miRNA profiles between pancreatic head and body/tail cancers 
A miRNA microarray platform (Agilent Human miRNA Microarray Kit version 14.0) analysis 
covering a total of 887 human miRNAs was performed to compare miRNA profiles between 4 
pairs strictly matched tumor tissues. They were strictly matched by gender, age (± 10 years), 
CA 19-9 (-: < 37 U/L / +: ≥37 U/L), TNM stage and histological differentiation. We found the 
majority of miRNAs, including 66 that have been reported to be associated with pancreatic 
cancer (Bloomston et al., 2007; Steele et al., 2011; Wang et al., 2011) (Table 4), were not 
significantly differentially expressed between these two subtypes of pancreatic cancer. This 
result was not surprising because all the 4 paired tissues were early stage PDACs.  
Table 4 The regulation of pancreatic cancer associated miRNAs in pancreatic body/tail 
cancer compared with pancreatic head cancer  
 
miRNA 
 
P value 
Fold 
change 
Regulation  Expression  
Body/tail  In PDAC Head  Body/tail  
hsa-miR-126* 0.010409 1.497677 up  5.083503 5.666229 
hsa-miR-455-3p 0.015982 2.201055 up  5.655185 6.79338 
hsa-miR-501-3p 0.019877 14.17093 down  2.385106 -1.43976 
hsa-miR-320d 0.020129 1.211291 down  8.939015 8.66247 
hsa-miR-320b 0.043105 1.154092 down Up  8.651562 8.444804 
hsa-miR-375 0.045640 5.612237 up down 5.595712 8.084288 
hsa-miR-146b-5p 0.074065 1.681926 up up 8.300115 9.050231 
hsa-miR-148a 0.076712 1.66357 up down 8.791904 9.526186 
hsa-miR-10b 0.114725 1.345653 up up 7.734763 8.16307 
hsa-miR-146b-3p 0.132901 1.114185 up up -3.17074 -3.01476 
hsa-miR-190 0.132901 1.114185 up up -3.17074 -3.01476 
hsa-miR-220a 0.132901 1.114185 up up -3.17074 -3.01476 
hsa-miR-220b 0.132901 1.114185 up up -3.17074 -3.01476 
hsa-miR-301b 0.132901 1.114185 up up -3.17074 -3.01476 
hsa-miR-424 0.148204 1.727851 up up 7.863314 8.652293 
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hsa-miR-21 0.203332 1.126374 up up 15.59998 15.77166 
hsa-miR-142-5p 0.226626 1.823401 up down 6.074466 6.941097 
hsa-miR-155 0.231053 1.420632 up up 7.461748 7.968281 
hsa-miR-139-3p 0.238155 1.480683 up down 3.542734 4.108997 
hsa-miR-148b 0.240651 1.357972 up down 6.37236 6.813814 
hsa-let-7d 0.265628 1.124965 up up 9.977742 10.14762 
hsa-miR-142-3p 0.300062 1.459817 up down 9.966391 10.51218 
hsa-miR-186 0.315269 1.293223 up up 6.044224 6.415195 
hsa-miR-125a-5p 0.336444 1.539021 up up 7.296905 7.918917 
hsa-miR-345 0.336664 6.250811 down down -0.37071 -3.01476 
hsa-miR-100 0.339273 1.266009 down up 9.68679 9.346502 
hsa-miR-212 0.345962 1.213576 up up 3.896251 4.175515 
hsa-miR-99a 0.346617 1.321411 down up 9.234546 8.832466 
hsa-miR-217 0.353879 4.632326 up down -3.17074 -0.95901 
hsa-miR-139-5p 0.366812 5.930201 up down -1.13349 1.434589 
hsa-miR-99b 0.377206 1.456922 up up 6.921114 7.464037 
hsa-miR-95 0.381705 4.517441 up up 3.342103 5.517609 
hsa-miR-92b 0.435211 3.030231 up up 1.836418 3.435846 
hsa-miR-301a 0.436055 1.886369 up up 3.992251 4.907863 
hsa-miR-199a-3p 0.457781 1.272802 up up 11.92264 12.27065 
hsa-miR-181a 0.463916 1.28108 up up 9.070984 9.428344 
hsa-miR-145 0.476132 1.298614 down up 10.74572 10.36875 
hsa-let-7i 0.485352 1.118322 up up 11.6396 11.80094 
hsa-miR-223 0.514289 1.628822 up up 10.28607 10.9899 
hsa-miR-15b 0.517299 1.1142 up up 9.94014 10.09615 
hsa-miR-205 0.529800 1.14686 down up -2.81707 -3.01476 
hsa-miR-376a 0.531236 1.189124 up up 6.985436 7.235335 
hsa-miR-96 0.551678 1.743802 down down 6.748685 5.946449 
hsa-miR-125b 0.552814 1.101894 down up 12.1143 11.97432 
hsa-miR-10a 0.558727 1.316333 up up 9.298406 9.69493 
hsa-miR-181b 0.561575 1.305739 up up 6.701516 7.086381 
hsa-miR-196a 0.574712 3.273563 up up 0.89446 2.605321 
hsa-miR-92a 0.593379 1.139964 down up 8.240348 8.051362 
hsa-miR-194 0.595127 2.105559 down up 8.641068 7.566865 
hsa-miR-130b 0.642252 1.211653 up down 6.15882 6.435797 
hsa-miR-181d 0.683719 1.22001 down up 4.655378 4.368486 
hsa-miR-27a 0.691632 1.100396 up up 11.82774 11.96576 
hsa-miR-107 0.760746 1.069993 down up 10.03742 9.939823 
hsa-miR-196b 0.787791 2.056219 up up 1.508813 2.548807 
hsa-miR-200b 0.804175 1.330283 down up 10.12447 9.712735 
hsa-miR-199a-5p 0.824088 1.083828 up up 10.63369 10.74983 
hsa-miR-143 0.829075 1.089806 down up 8.853937 8.729867 
hsa-miR-429 0.856847 1.224759 down up 7.325429 7.032932 
hsa-miR-125a-3p 0.863100 1.096062 up up 6.449531 6.58186 
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hsa-miR-146a 0.866126 1.108128 down up 8.158847 8.010722 
hsa-miR-23a 0.873887 1.037518 up up 12.4273 12.48044 
hsa-miR-16 0.874665 1.034553 down up 11.48334 11.43433 
hsa-miR-20a 0.887991 1.046063 down up 9.144461 9.079493 
hsa-miR-181c 0.907418 1.059798 up up 5.025995 5.109785 
hsa-miR-222 0.911535 1.06031 down up 7.131722 7.047236 
hsa-miR-24 0.912683 1.036835 up up 11.71964 11.77182 
hsa-miR-23b 0.936822 1.023272 up up 11.14156 11.17475 
hsa-miR-31 0.941169 1.230366 up up 3.874156 4.173243 
hsa-miR-103 0.964565 1.011592 down up 10.36751 10.35088 
hsa-miR-221 0.969799 1.015645 up up 7.43665 7.459047 
hsa-miR-210 0.977395 1.042275 up up 6.265573 6.325307 
hsa-miR-200c 0.994024 1.009893 down up 9.257704 9.2435 
Of note, we found 6 miRNAs that were significantly differentially expressed (P < 0.05) (Figure 
5). There were higher expressions of miR-126*, miR-455-3p and miR-375, and lower 
expressions of miR-501-3p, miR-320d and miR-320b in pancreatic body/tail cancer 
compared with their matched pancreatic head cancer (Table 4). If we take fold change and 
Rank Sum difference into consideration, miR-501-3p was the only candidate for further study 
with P < 0.05, fold change > 2 and largest Rank Sum difference. But we also take miR-375 
into further verification procedures because it was reported to be a potent tumor suppressor 
in pancreatic cancer (Basu et al., 2011). 
 
Figure 5. A hierarchic cluster heat map showing the 6 differentially expressed miRNAs between 
pancreatic head cancer and pancreatic body/tail cancer samples. Three (miR-126*, miR-455-3p and 
miR-375) were higher expressed, and another three (miR-320b, miR-320d and miR-501-3p) were 
lower expressed in pancreatic body/tail cancer. 
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3.1.2 Lower expression of miR-501-3p and higher expression of miR-375 in 
pancreatic body/tail cancer  
A total of 15 paired tissues were used for the subsequent quantitative reverse transcription 
real-time polymerase chain reaction (qRT-PCR) validations. Clinical and histopathologic 
variables for the patients included in this study were listed in Table 5. 
Table 5 Tumor samples used for analysis 
 Gender Age 
(year) 
CA 19-9 
(ng/ml) 
TNM staging Histological 
differentiation 
  Paired 1 Female 68  23  T2N0M0 (I B) Moderate-poor 
 Female 62  38  T2N0M0 (I B) Moderate-poor 
  Paired 2 Male 59  12000  T3N1M0 (II B) Moderate-poor 
 Male 59  3885  T2N1M0 (II B) Moderate-poor 
  Paired 3 Male 62  2609  T3N1M0 (II B) Moderate-poor 
 Male 59 700  T3N1M0 (II B) Moderate-poor 
  Paired 4 Male 61 986 T2N1M0 (II B) Poor 
 Male 66  11525  T2N1M0 (II B) Poor 
  Paired 5 Female 61 995 T3N0M0 (II A) Moderate 
 Female 53 531 T3N0M0 (II A) Moderate 
  Paired 6 Male  62 150 T3N0M0 (II A) Moderate 
 Male 55 534 T3N0M0 (II A) Moderate 
  Paired 7 Male 55 12000 T3N0M0 (II A) Moderate-poor 
 Male 59 700 T3N0M0 (II A) Moderate-poor 
  Paired 8 Male 63 894 T3N0M0 (II A) Poor  
 Male 70 961 T3N0M0 (II A) Poor  
  Paired 9 Male 70 79 T3N0M0 (II A) Moderate 
 Male 75  271  T3N0M0 (II A) Moderate 
Paired 10 Female 75 572 T3N1M0 (II B) Moderate 
 Female 50 951  T2N1M0 (II B) Moderate 
Paired 11 Male 79  1142  T3N1M0 (II B) Moderate-poor 
 Male 81 240 T3N1M0 (II B) Moderate-poor 
  Paired 12 Male 52 471 T3N1M0 (II B) Moderate-poor 
 Male 71 11246 T3N1M0 (II B) Moderate-poor 
  Paired 13 Male 61 4 T3N0M0 (II A)  Moderate 
 Male 38 17 T3N0M0 (II A) Moderate 
Paired 14 Female 38 54 T3N1M0 (II B) Moderate 
 Female 42 173 T2N1M0 (II B) Moderate 
Paired 15 Male 55 1598 T2N1M0 (II B) Moderate 
 Male 56 71 T3N1M0 (II B) Moderate 
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We found the results were consistent with the one from miRNA microarray profiles that 
miR-501-3p expression was significantly decreased (P = 0.004, fold change = 2.99) whereas 
miR-375 expression was increased (P = 0.040, fold change = 1.88) in pancreatic body/tail 
cancer than those in pancreatic head cancer (Figure 6).  
From the higher expression of miR-375, a tumor suppressor in pancreatic body/tail cancer, 
we hypothesized that pancreatic body/tail cancer might be ‘less’ malignant than pancreatic 
head cancer. However, the role of miR-501-3p in cancer is definitely unknown and should be 
further evaluated. 
 
Figure 6. Box plot representing the expression of miRNAs. As assessed by real-time quantitative PCR, 
pancreatic body/tail cancer showed significantly lower expression of miR-501-3p (A) and higher 
expression of miR-375 (B). 
3.1.3 Low expression of miR-501-3p contributes to low-risk of tumor 
recurrence 
There were 9 out of 30 patients (30.0%) who were found to suffer from tumor recurrence 
during the follow up (2.3 ± 0.8 years) and the majority (8/9, 88.9%) occurred within 1 year 
after operation. The recurrence rate was significantly lower in pancreatic body/tail cancer 
than that in pancreatic head cancer (13.3% vs. 46.7%, P = 0.046). Furthermore, from the 
Kaplan-Meier survival curves, we could find that both patient cumulative survival and 
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tumor-free survival were higher in pancreatic body/tail cancer than pancreatic head cancer 
(Figure 7). 
 
Figure 7. Prognosis in patients with pancreatic body/tail cancer and those with pancreatic head cancer. 
The Kaplan-Meier curves for comparison of tumor-free survival (A) and patient cumulative survival (B) 
between patients with pancreatic head cancer and those with pancreatic body/tail cancer. Pancreatic 
body/tail cancer showed significantly higher tumor-free survival than its matched pancreatic head 
cancer (P = 0.030). 
To determine the role of miRNAs in tumor recurrence, we then carried out COX regression 
analysis and found that high expression of miR-501-3p (P = 0.034; Risk Ratio = 2.322, 95%CI: 
1.068-5.048) but not miR-375 was significantly associated with tumor recurrence after 
surgery. Patients with high expression of miR-501-3p showed a significantly lower tumor-free 
survival than those with low expression of miR-501-3p (P = 0.031, Figure 8A). The cutoff 
value was selected using receiver operating characteristic curve. In addition, we compared 
the miR-501-3p expression between patients with and without tumor recurrence and found a 
significantly higher expression of miR-501-3p in those with tumor recurrence (P = 0.017, 
Figure 8B). The data indicated that lower expression of miR-501-3p in pancreatic body/tail 
cancer might contribute to lower risk of tumor recurrence. 
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Figure 8. Low expression of miR-501-3p contributes to low-risk of tumor recurrence in all 30 patients 
with PDAC. The Kaplan-Meier curves for comparison between patient with high expression of 
miR-501-3p and those with low expression of miR-501-3p (A); Box plot represented that patients with 
recurrence after operation showed significantly higher expression of miR-501-3p (B).  
 
3.2  In vitro studies: miR-501-3p leads to morphological changes of 
pancreatic cancer cells 
To confirm our hypothesis, we performed an in vitro study to evaluate the role of miR-501-3p 
in PDAC cells. Two frequently used pancreatic cancer cell lines, Panc-1 and Colo357, were 
transfected with miR-501-3p Mimics and Inhibitors. Since miRNA Mimics and miRNA 
Inhibitors have different chemical structures, miRNA Mimics are modified double-stranded 
RNAs while miRNA Inhibitors are modified single-stranded RNA molecules, we will present 
the results from Mimics and Inhibitors separately. Cell proliferation, viability, invasion, 
chemo-resistance and TRAIL-sensitivity were compared between Mimic group and its control, 
and between Inhibitor and its control, respectively. Each experiment was repeated 3 times 
under the same conditions. 
3.2.1 miR-501-3p and proliferation 
PDAC cells were transfected with miR-501-3p Mimics, Inhibitors and their controls. After 
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transfection for 72 hours, cells were trypsinized from 6-well plates and counted. We found 
significantly fewer cells in the Mimics group than its negative control (P = 0.002 for Panc-1, P 
= 0.013 for Colo357) but no significant difference was found between Inhibitor group and its 
negative controls (Figure 9). The result indicates that miR-501-3p may reduce proliferation of 
PDAC cells. 
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Figure 9. Relative cell numbers in the PDAC cells transfected with (A) miR-501-3p Mimics and its 
negative control, (B) miR-501-3p Inhibitors and its negative control. Cell numbers were normalized to 
the negative control groups. *: P < 0.05. PDAC cells were seeded in the 6-well plates 1.7 × 105/well for 
Panc-1 and 2.0 × 105/well for Colo357 respectively, and counted 72 hours after transfection. The 
experiment was repeated 4 times under the same conditions. The figures showed the mean value (bar) 
and standard deviation (error line).  
 
3.2.2 miR-501-3p and cell death 
Deregulation of proliferation, together with a reduction of cell death, is necessary for tumor 
development, progression, and therapy-resistance. From the microscopical observation, we 
suspected that miR-501-3p may lead to reduced proliferation but also decreased cell death. 
Therefore, we performed flow cytometry (FCM) to assess the apoptosis and death rates in 
PDAC cells. Because we did this experiment in Hangzhou, China, using different source of 
Panc-1 cells compared with the one in Kiel, the results are provided as supplemental data. 
We found a trend that more apoptotic cells in the Inhibitor group than its negative control 
(supplemental Figure 1).  
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In addition, because caspase-8 is an initiator caspase in the extrinsic apoptotic pathway, we 
tested the caspase-8 protein levels in PDAC cells transfected with Mimics, Inhibitors, or their 
controls. We found that the cleaved caspase-8 (particularly p18 and p13) was weaker in 
Mimics group than its negative control, but much stronger in Inhibitors group than its negative 
control, particularly in Panc-1 cells (Figure 10).  
(A)  (B)  
Figure 10. The expression of caspase8 protein in Colo357 and Panc-1 cells transfected with (A) 
miR-501-3p Mimics and its negative control, (B) miR-501-3p Inhibitors and its negative control. Cell 
lysate was obtained 72 hours after transfection. The arrows indicate the cleaved capspase-8 (p43/41: 
43/41 kDa, p18: 18 kDa and p13: 13 kDa).  
 
3.2.3 miR-501-3p and invasion 
Cell invasion is a crucial step in metastasis and the ability of cancer cells to undergo invasion 
allow them to enter lymphatic and blood vessels for dissemination (Chambers et al., 2002). 
Tumor cell motility is an essential step in metastasis and a hallmark of invasion, and ECM 
adhesion is a key mediator in cell motility and in the process of metastasis (Le Devedec et al., 
2010; Ridley et al., 2003). In the first part of our study, we found that miR-501-3p might be 
associated with metastasis/recurrence of pancreatic cancer. Therefore, evaluating the effect 
of miR-501-3p on invasion ability in vitro could be a strong evidence for proving the clues for 
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clinical findings.  
PDAC is characterized by a pronounced fibrotic reaction composed primarily of type I 
collagen. PDAC cells have been shown to respond to collagen I by becoming more motile 
and invasive although collagen I functions as a barrier to invasion (Shields et al., 2011). Here, 
we used a type I collagen coated transwell chamber for testing the invasion ability of PDAC 
cells. 
After transfection for 72 hours, 5.0 × 104 cells/well PDAC cells in reduced serum medium 
(0.5%) were seeded into the upper chamber. After incubation for 24 hours, the invasion ability 
was assessed by crystal violet assay. We found significantly higher invasion rate in the 
Mimics group (P = 0.017 for Panc1, P = 0.068 for Colo357) and less invasion rate in the 
Inhibitors group (P = 0.003 for Panc1, P = 0.001 for Colo357) compared with their respective 
negative controls, which indicates that miR-501-3p may promote invasion in PDAC cells 
(Figure 11).  
This result was consistent with the clinical finding, which suggests that pancreatic body/tail 
cancer is associated with a reduced miR-501-3p expression and consequently a less 
invasion ability compared with pancreatic head cancer. The possible mechanism might be 
explained by the decreased E-Cadherin levels in the Mimics group and increased E-Cadherin 
levels in the Inhibitors group, which is shown in the following part (3.3). 
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Figure 11. Invasion ability in the PDAC cells transfected with miR-501-3p Mimics, Inhibitors and their 
negative controls. PDAC cells were seeded in the Collagen I-coated transwell chambers as 5.0 × 
104/well, and incubated for 24 hours. (A) and (B) showed the median value (bar) of invasion rate 
(because of non-normal distribution) between Mimics and its negative control, and Inhibitors and its 
negative control; (C) and (D) showed the mean value (bar) and standard deviation (error line) of 
relative invasion rate (normalized to the control groups) between Mimics and its negative control, and 
Inhibitor and its negative control. *: P < 0.05. Statistical analysis was performed only in (C) and (D).  
 
3.2.4 miR-501-3p and chemo-resistance 
Chemo and/or radiotherapy remain the first choice of palliative treatment for PDAC, and 
promote cancer cell death primarily by the induction of apoptosis. Gemcitabine is now widely 
used as the first line chemotherapy for the end stage pancreatic cancer. To better evaluate 
the role of miR-501-3p in the chemo-induced apoptosis, we tested the cell viability in both 
chemo-resistant cell line (Panc-1) and chemo-sensitive cell line (Colo357).  
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PDAC cells were transfected with miR-501-3p Mimics, Inhibitors, or their negative controls for 
72 hours and then seeded into the 96-well plates. Gemcitabine (1 ug/ml) was given in the 
treatment group when the cells had settled down. After 48 hours, the viable cells were 
measured by crystal violet assay (Figure 12). We found more viable cells in Panc-1 than that 
in Colo357, which proved again that Panc-1 were Gemcitabine-resistant cell line while 
Colo357 was highly sensitive to Gemcitabine treatment. However, no significant difference 
was found between Mimics and their control or between Inhibitors and their control in both 
cell lines. It seems that miR-501-3p is not associated with the chemo-resistance neither in 
high nor low chemo-sensitive cell lines. 
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Figure 12. Viable cells in Panc-1 and Colo357 transfected with miR-501-3p Mimics, Inhibitors and their 
negative controls. PDAC cells were seeded in the 96-well plate as 1.0 × 104/well at 72 hours after 
transfection, and incubated for 48 hours after treatment of Gemcitabine (1 ug/ml). (A) and (B): the 
percent of viable cells. (C) and (D): relative viable cells. The cell viability was normalized to the control 
groups. The experiment was repeated 3 times under the same conditions. The figures showed the 
mean value (bar) and standard deviation (error line).  
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3.2.5 miR-501-3p and TRAIL-induced apoptosis 
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the tumor 
necrosis factor (TNF) superfamily, selectively induces apoptosis in a variety of human cancer 
cell lines, with no toxicity against normal tissues (Almasan et al., 2003). TRAIL induces 
programmed death in various cancer cells through its interaction with the death receptors, 
TRAIL-receptor 1 (TRAIL-R1 or DR4) and/or TRAIL-receptor 2 (TRAIL-R2 or DR5), which 
contain the intracellular death domain (DD) that is essential for the apoptosis signal. In this 
study, we evaluate the effect of miR-501-3p on the TRAIL-induced death and test the 
expression of TRAIL-R1 and TRAIL-R2 after regulation of miR-501-3p levels. 
After transfection for 72 hours, 1.0 × 104 cells/well PDAC cells were seeded into 96-well 
plates. TRAIL (100 ng/ml) was added into the treatment group 24 hours after cell seeding. 
The cell viability was tested using crystal violet assay after additional 24 hours. We found no 
significant difference between Mimic group and its control, or Inhibitor group and its control in 
Colo357 cells. However, in Panc-1 cells, Mimic group showed higher viability than its control 
(P = 0.027) (Figure 13). 
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Figure 13. Cell viability in the PDAC cells treated with TRAIL. (A) and (B): cell viability between Mimics 
and its negative control, and Inhibitor and its negative control. (C) and (D): relative cell viability 
(normalized to the control groups) between Mimics and its negative control, and Inhibitors and its 
negative control. *: P < 0.05. Statistical analysis was performed only in (C) and (D). PDAC cells were 
seeded in the 96-well plate as 1.0 × 104/well at 72 hours after transfection, and incubated for 24 hours 
after treatment of TRAIL (100 ng/ml). The experiment was repeated 3 times under the same conditions. 
The figures showed the mean value (bar) and standard deviation (error line).  
To further study the effect of miR-501-3p on TRAIL signaling pathway, we also tested the 
TRAIL-R1 and TRAIL-R2 protein levels in different groups, since the decreased expression of 
death receptors (TRAIL-R1 and TRAIL-R2) in cancer cells is involved in TRAIL resistance 
(Thorburn et al., 2008). Interestingly, we found decreased expression of TRAIL-R1 and 
TRAIL-R2 in the Mimics group compared with its negative control in Panc-1 cells but not in 
Colo357 cells (Figure 14). This result was consistent with the TRAIL treatment experiment 
and indicated that decreased TRAIL-sensitivity after up-regulation of miR-501-3p may due to 
the decreased TRAIL-R1 and TRAIL-R2 levels in Panc-1 cells.  
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(A)  (B)  
Figure 14. The expression of TRAIL-R1 and TRAIL-R2 protein in Colo357 and Panc-1 cells transfected 
with (A) miR-501-3p Mimics and its negative control, (B) miR-501-3p Inhibitors and its negative control. 
Cell lysates were obtained 72 hours after transfection. The experiment was repeated 3 times and the 
representative one was shown.  
 
3.3  miR-501-3p regulates cell adhesion molecules 
3.3.1 miRNA target search 
The target genes for miR-501-3p have not been reported so far. Therefore, Open-source 
software using different algorithms based on sequence complementarity, such as miRBase 
(http://www.mirbase.org/), TargetScan (http://www.targetscan.org), PicTar 
(http://pictar.mdc-berlin.de/), DIANA-microT (http://diana.cslab.ece.ntua.gr/microT/) and 
miRanda (www.microrna.org), were used for miRNA target predictions.  
MiR-501-3p has not been enrolled in PicTar database. We found 223 conserved targets from 
TargetScan (TargetScanHuman 6.0), 113 targets from DIANA-microT (Diana microT- v4) with 
a threshold of 0.5 for high precision, 1676 targets for miRanda with “good” mirSVR score 
(<−0.1) and seed regions. A total of 28 target genes (AFF4, ARID5B, CDH5, CIT, CPEB2, 
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CSDE1, DCUN1D5, GAN, JHDM1D, KPNA4, NONO, NR1D2, ODZ2, PCDH9, PLD3, 
PPP2R5E, PPP3CA, PPP3CC, PTBP2, RCC2, RNF144A, STIM2, TARDBP, TRERF1, 
UBE2E2, ZFHX4, ZIC4, ZMYM4 and ZRANB2) were overlapped among all the 3 databases. 
Of the 28 genes, CDH5 (Le Guelte et al., 2011), JHDM1D (Osawa et al., 2011), PCDH9 
(Wang et al., 2012), PPP3CA (Singh et al., 2008), PPP3CC (Hornstein et al., 2008), PTBP2 
(Cheung et al., 2009), RNF144A (Marzook et al., 2012) and STIM2 (Aytes et al., 2012) were 
reported to be associated with cancer (Table 6).  
Table 6 Potential target gene information * 
Target 
gene 
Product  Function in cancer Tissue/cell lines Reports 
No.** 
CDH5 cadherin 5, type 2 
(vascular 
endothelium) 
Tumor-associated 
angiogenesis (oncogene),  
keep vascular endothelial 
barrier, reduce 
permeability (TSG) 
Various cell lines 11 
 
JHDM1D jumonji C domain 
containing histone 
demethylase 1 
homolog D 
suppress angiogenesis 
(TSG) 
Human cervical carcinoma (HeLa), 
hepatocellular carcinoma (HepG2), 
epidermoid carcinoma (A431), 
glioblastoma (T98G) 
1 
PCDH9 protocadherin 9 Improve prognosis (TSG)  Glioma 3 
PPP3CA protein 
phosphatase 3, 
catalytic subunit, 
alpha isozyme 
Apoptosis (TSG) Prostate cancer cells 4 
PPP3CC protein 
phosphatase 3, 
catalytic subunit, 
gamma isozyme 
reduce recurrence (TSG) Prostate cancer tissue and cells  2 
PTBP2 polypyrimidine 
tract binding 
protein 2 
Promote proliferation and 
migration (oncogene) 
Human glioma cell lines U251 and 
LN229 
4 
RNF144A ring finger protein 
144A 
Inhibit migration and 
invasion (TSG) 
Human breast cancer cells (MCF-7), 
cervical carcinoma cells (HeLa) 
1 
STIM2 stromal 
interaction 
molecule 2 
reduce proliferation (TSG) colon cancer cell lines, 
breast cancer 
11 
*: The genes were listed according to the prediction score.  
**: Number of reports was calculated according to the results from PubMed by searching the keywords 
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of ‘gene name’ and ‘cancer’. 
.TSG: tumor suppressor gene. 
 
3.3.2 Differentially expressed E- and VE-Cadherin in various PDAC cell lines 
Cadherins are a class of type I transmembrane proteins. They play important roles in cell 
adhesion, ensuring that cells can bind together in tissues. Because three of the cadherins 
(cadherin 5, protocadherin 9 and protocadherin 17) have been listed as the potential direct 
targets of miR-501-3p in TargetScan, DIANA-microT and miRanda databases, we paid great 
attention and interest in the association between miR-501-3p and cadherins. 
E-Cadherin is the most well studied member of the cadherin family. The most important event 
of EMT is loss of E-Cadherin, which demonstrates a prerequisite for epithelial tumor cell 
invasion (Guarino et al., 2007). VE-Cadherin (CD144) is traditionally considered a strictly 
endothelial specific adhesion molecule located at junctions between endothelial cells. 
Although VE-Cadherin has recently been found in some non-endothelial cells such as breast 
cancer cells (Labelle et al., 2008), it is still unknown whether VE-Cadherin is expressed in 
PDAC cells.  
We test the expression of E- and VE-Cadherin in several frequently used PDAC cell lines, 
including Capan-1, Capan-2, Panc-1, PancII-1, Panc89, BxPc-3 and Colo357. Among these 
seven cell lines, only two (Colo357 and Panc89) expressed VE-Cadherin protein. While the 
levels of VE-Cadherin were very low in Panc89, only Colo357 showed high levels of 
VE-Cadherin protein (Figure 15). According to the ultrastructural grading system (Sipos et al., 
2003), both Colo357 and Panc89 are grade 2 cell lines. Neither the less malignant grade 1 
cell lines (Capan-1 and Capan-2) nor the more malignant grade 3 cell lines (Panc-1, PancTu-I) 
express VE-Cadherin. The role of VE-Cadherin in the PDAC carcinogenesis and tumor 
progression should be further studied. 
Compared with VE-Cadherin, all studied PDAC cell lines expressed E-Cadherin. Only Panc-1 
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showed very weak expression but all other cells presented very high E-Cadherin protein 
levels (Figure 15). E-Cadherin is a marker for EMT and can function as a parameter of 
‘malignancy’. According to the ultrastructural grading system (Sipos et al., 2003), higher 
grade of PDAC cells were associated lower expression of E-Cadherin (Figure 15). Taken 
together, Colo357 (highly expresses VE-Cadherin) and Panc-1 (lowly expresses E-Cadherin) 
are two special cell lines compared with other PDAC cell lines. Thus, we used these two cell 
lines as a model for the further study.  
 
Figure 15. The expression of E- and VE-Cadherin protein in several PDAC cell lines.  
 
3.3.3 miR-501-3p regulates E- and VE-Cadherin expression  
To verify the possible relation between miR-501-3p and E-Cadherin and VE-Cadherin 
respectively in pancreatic cancer, we tested the protein levels after regulation of miR-501-3p 
in Colo357 and Panc-1 cells. We found reduced E-Cadherin protein expression in the Mimics 
group and increased protein expression in the Inhibitors group compared with their respective 
negative controls in both cell lines (Figure 16). In Colo357, the only high expressing 
VE-Cadherin cells, both E- and VE-Cadherin expressions decreased after transfection with 
miR-501-3p Mimics but increased with miR-501-3p Inhibitors compared to the negative 
controls (Figure 16). This suggests that miR-501-3p regulates E- and VE-Cadherin 
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expression. Because there is a direct role for E-Cadherin in the suppression of tumor invasion 
(Wong et al., 2003), the decreased E-Cadherin in the Mimics group might explain the 
increased invasion ability in both Colo357 and Panc-1 cells.  
(A)  (B)  
Figure 16. The expression of E- and VE-Cadherin protein in Colo357 and Panc-1 cells transfected with 
(A) miR-501-3p Mimics and its negative control, (B) miR-501-3p Inhibitors and its negative control. Cell 
lysate was obtained 72 hours after transfection.  
 
3.3.4 Target VE-Cadherin verification 
CDH5 is the leading predicted target genes of miR-501-3p. Its encoded protein VE-Cadherin 
is well known to be related to tumor invasion and metastasis (Le Guelte et al., 2011) and from 
the previous Western Blot analysis we have found that miR-501-3p might target VE-Cadherin. 
Therefore, CDH5 was chosen for the further verification (Table 7).  
We cloned the 3′-UTR region of CDH5 (WT-3′-UTR) or its mutated (MUT-3′-UTR) 
downstream of the firefly luciferase reporter gene, and then co-transfected with miR-501-3p 
Mimics/Inhibitors or its negative control into HUVEC cells (source: The First Affiliated Hospital, 
Zhejiang University School of Medicine, Hangzhou, China). The luciferase activity of the WT 
construct of CDH5 3′-UTR was significantly reduced/increased in the presence/absence of 
miR-501-3p compared with the negative control (P < 0.05). However, such an effect was not 
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observed in the MUT construct of CDH5 3′-UTR (Figure 17). These data suggest a direct and 
specific interaction of miR-501-3p on CDH5 3’UTR. 
 
Table 7 Targetscanhuman 6.0 for the information of target gene 
Gene 
symbo
l 
Seed 
match 
3’UTR 
position 
Context
+score 
Conserve
d branch 
length 
predicted consequential pairing of target 
region and miRNA 
CDH5 7mer-m8 1554-156
0 
-0.22 2.179 (3’ UTR) 
5’ ...UAUAUUGGCCAAACUGGUGCAUG...  
(miRNA) 3’    
UCUUAGGAACGGGCCCACGUAA  
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Figure 17. CDH5 is a miR-501-3p target gene. (A): The luciferase activity of the WT construct of CDH5 
3’-UTR was significantly reduced in the miR-501-3p mimics than its negative control. (B): The 
luciferase activity of the WT construct of CDH5 3’-UTR was significantly increased in the miR-501-3p 
inhibitors compared to its negative control. *: P < 0.05. Firefly luciferase activities were normalized to 
Renilla luciferase activities. Data were normalized to the negative control groups. The experiment was 
repeated 3 times under the same conditions. The figures showed the mean value (bar) and standard 
deviation (error line). Cell source: The First Affiliated Hospital, Zhejiang University School of Medicine, 
Hangzhou, China 
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4. Discussion 
4.1  Pancreatic body/tail cancer is associated with better prognosis 
The survival rate of pancreatic cancer (i.e. PDAC) is the ‘worst’ of all major cancers (e.g. lung 
cancer, liver cancer, gastric cancer, colon cancer, breast cancer, prostate cancer) and mostly 
depends on the tumor stage. Stage I-II is commonly considered as the stage during which the 
surgical treatment is most effective. Although surgery has been continuously improved, 
patients with early stage pancreatic cancer still have a high recurrence rate after curative 
resection, as was shown by this study that one third of all patients suffered from tumor 
recurrence during the follow up. 
Besides tumor stage, the prognosis of pancreatic cancer is also associated with the tumor site. 
The theory of different mechanisms in carcinogenesis of tumors at different locations and the 
importance of subsite division have been supported by several pioneering studies. In colon 
cancer, a number of studies have demonstrated that right- and left-sided tumors exhibit 
different genetic, biological and demographical characteristics and risk factors, suggesting 
that the carcinogenesis and tumor progression of colon cancer may differ with tumor 
localization (Slattery et al., 2011). In pancreatic serous cystic neoplasm, tumor location in the 
head of pancreas was independently associated with local invasiveness (Khashab et al., 
2011).  
For PDAC, pancreatic body/tail cancer has been long-term considered as a ‘more’ malignant 
subtype compared with pancreatic head cancer. Clinically, we see patients with pancreatic 
body/tail cancer more likely to be at advanced stage. The symptoms, such as jaundice and 
nausea, which could be a signal for early diagnosis, would rarely happen in patients with early 
stage pancreatic body/tail cancer. Consequently, pancreatic body/tail cancer is commonly 
associated with a dismal prognosis. The overall survival is much lower in pancreatic body/tail 
cancer than that in pancreatic head cancer.  
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However, recently, a large sample study from SEER registries of Unite States including 
information from 43,946 patients (Lau et al., 2010) revealed that pancreatic body/tail cancer 
had a significant higher survival than pancreatic head cancer if both tumors were at the same 
local-stage. Interestingly, we could find that the old database of Unite States (1985-1995) also 
presented a higher survival rate for local-stage pancreatic tail cancer compared with 
local-stage pancreatic head cancer (Sener et al., 1999). Therefore, we started to hypothesize 
whether the pancreatic body/tail cancer is ‘more’ malignant than pancreatic head cancer in 
nature. However, the data from both clinical and genetical comparison between the pancreatic 
head cancer and body/tail cancer is rather limited. Given the complex and heterogeneous 
nature of PDAC, it is reasonable to hypothesize that these two subtypes may be separated 
from each other and differ not only in phenotype but also in genotype. Furthermore, we 
suppose that the two subtypes of PDAC may be differing in their malignant characteristics. 
This study performed the first comparison between pancreatic body/tail and head cancers 
using strictly matched early stage cancers. We found that patients with early stage pancreatic 
body/tail cancers presented higher survival rate than those with paired pancreatic head 
cancers. This finding was consistent with the previous studies mentioned before. Furthermore, 
we found patients with early stage pancreatic body/tail cancers had a lower tumor recurrence 
rate after curative resection.  
Tumor recurrence is defined as the return of tumor after radical treatment and after a period of 
time during which the tumor cannot be detected. There are three types of tumor recurrence: 
local recurrence (the same tumor occurs where it started), regional recurrence (the same 
tumor occurs in the lymph nodes near the site of origin), and distant recurrence that is also 
called metastatic recurrence (the same tumor occurs somewhere else in the body, distant 
from where it started). The detailed molecular mechanism of tumor recurrence is still unclear. 
The well-known risk factors are advanced tumor stage, poor histological differentiation and 
highly malignant tumor subtype. In addition, surgical procedure and surgeon have great 
impact on the prognosis. For instance, the better observance of tumor-free principle, regional 
lymph node dissection and appropriate surgical margin are associated with better prognosis. 
Furthermore, surgery itself by inducing a strong inflammatory stimulation may be a facilitator 
 54
of the recurrence/metastatic process (Neeman et al., 2012; Tepel et al., 2006). To some extent, 
high tumor recurrence rate could be a marker for a high malignant potential, especially under 
the condition in this study that the same surgeon performed all operations, and tumors were at 
the same stage and histological differentiation. These results indicate that pancreatic body/tail 
cancer might be ‘less’ malignant than pancreatic head cancer.  
 
4.2  Lower expression of miR-501-3p in pancreatic body/tail cancer 
indicates a lower invasive phenotype 
4.2.1 miRNA profiles in pancreatic cancer 
In miRBase database (Release 19) (http://www.mirbase.org), 2042 mature human miRNAs 
are reported and more miRNAs are likely to be found. As the development of new 
technologies, microarray-based approaches has allowed genome-wide, high throughput 
screening for novel candidates involved in the pathogenesis of a variety of cancers. Aberrant 
expression of miRNAs has been detected in many human diseases including PDAC. When 
searching the US National Library of Medicine (PubMed) using keywords ‘pancreatic cancer’ 
and ‘miRNA’, we found that a total of 224 references are listed 
(http://www.ncbi.nlm.nih.gov/pubmed). Among the 224 publications, 204 and 187 were 
published in the past 5 and 3 years, respectively. It is becoming a very hot and promising filed 
for identifying the PDAC associated miRNAs expression pattern.  
Current clinical screening and diagnostic management of patients with PDAC is mainly based 
on imaging techniques such as contrast-enhanced multi-detector computer tomography (CT) 
scan, positron emission tomography (PET) scan and diffusion-weighted magnetic resonance 
imaging. However, due to the relative low sensitivity and specificity, such techniques may only 
be used for the evaluation of existing of solid tumors (> 20 mm2) (Fukukura et al., 2012). 
Therefore, there is a strong need for identification of novel biomarkers to predict the 
development of PDAC and early diagnosis. 
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During the last 5 years, a number of studies have compared the miRNA expression profiles 
either between PDAC and normal pancreas, or between PDAC and chronic pancreatitis, and 
even between PDAC and different stages of PanINs, using blood or tissue samples 
(Bloomston et al., 2007; Jamieson et al., 2012; Szafranska et al., 2007; Wang et al., 2011; Yu 
et al., 2012). Recently, considering a high volume (~1.5 L) of pancreatic juice production and 
excretion into the bowel, it has been hypothesized that precancerous or early cancer-related 
molecular changes may be detectable in feces of pancreatic cancer patients. A specific 
miRNA pattern has been found in stool as miRNA biomarkers for PDAC screening (Link et al., 
2012). Taken together, advanced technologies have helped us to find a series of frequently 
dysregulated miRNAs in PDAC, such as miR-21, miR-155 and miR-196a (Bhat et al., 2012). 
4.2.2 Different miRNA expressions between pancreatic head and body/tail 
cancers  
Although a number of studies have identified PDAC-associated miRNA expression pattern, 
there is still a lack of comparison between pancreatic head and body/tail cancers. We could 
only find indirect evidence from the comparison between two cell lines as typical 
representatives originating from pancreatic head cancer (Panc-1) and body/tail cancer (MIA 
PaCa-2), respectively. Studies have shown specifically altered miRNAs between PDAC cell 
lines and human pancreatic ductal epithelium control cell lines, and between subgroups of 
PDAC cell lines with different invasion or metastasis properties (Ji et al., 2009; Kent et al., 
2009; Mees et al., 2009). From these studies covering a large panel of miRNAs, we could find 
several differentially expressed miRNAs between Panc-1 and MIA PaCa-2, such as miR-10b, 
miR-15b, miR-18a, miR-21, miR-22, miR-125, miR-155, miR-181 and miR-196a (Ji et al., 
2009; Kent et al., 2009).  
For the first time, we performed miRNA microarray screening to provide direct evidence of 
different miRNA patterns between pancreatic head and body/tail cancers. It is not surprising 
that the expressions of the majority of miRNAs in this analysis were similar between 
pancreatic body/tail cancer and head cancer because both subtypes are essentially PDAC. 
However, as expected, there were also significantly differentially expressed miRNAs between 
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the two subtypes. Among 887 detected human miRNAs, 6 were found either remarkably 
higher or lower expressed in pancreatic body/tail cancer compared with those in pancreatic 
head cancer. According to the selection criteria, the two most statistically significant miRNAs 
(miR-501-3p and miR-375) were further verified by qRT-PCR. We hypothesized that 
miR-501-3p and miR-375 may encode the diversity between pancreatic head and body/tail 
cancer. 
miR-375 was firstly thought to be only expressed in endocrine pancreatic cells (islet β-cells 
and non-β-cells) (Poy et al., 2009), but increasing evidence shows that it could be also 
expressed in other tissues (Ding et al., 2010; Xu et al., 2011b). miR-375 has great impact on 
pancreatic islet cell viability and function, and plays important role in the regulation of insulin 
secretion and glucose metabolism, and acts as a key determinant of blood glucose 
homeostasis (Lynn, 2009). Furthermore, miR-375 is also closely associated with pancreatic 
cancer. Studies have demonstrated a down-regulation of miR-375 in pancreatic cancer (Basu 
et al., 2011; Bloomston et al., 2007; Lee et al., 2007; Szafranska et al., 2007). It can act as a 
tumor suppressor and targeted several oncogenes such as PDK1 (a master regulator of 
oncogenic phosphoinositide-3 kinase signaling), Janus kinase 2 (JAK2) and insulin-like 
growth factor 1 receptor (IGF1R), resulting in decreased cancer cell growth, viability and 
invasion (Ding et al., 2010; Kong et al., 2012; Xu et al., 2011b). Higher expression of miR-375 
in pancreatic body/tail cancer could provide evidence for a ‘reduced’ malignancy of pancreatic 
body/tail cancer than pancreatic head cancer.  
Unlike miR-375, miR-501-3p has not yet been reported in human cancers. It has not been 
reported to be highly differentially expressed between PDAC and normal pancreatic tissues. 
Therefore, the role of miR-501-3p in pancreatic cancer needed further functional analyses. 
4.2.3 miR-501-3p is associated with high invasiveness  
Our results demonstrated that miR-501-3p was significantly associated with pancreatic cancer 
recurrence after surgery. High expression of miR-501-3p was a risk factor of tumor recurrence, 
which suggests that miR-501-3p may be a potential biomarker for tumor recurrence after 
surgical therapy. These results indicate that pancreatic body/tail cancer could be 
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characterized by a lower expression of miR-501-3p, which contributes to a lower recurrence 
risk, compared with pancreatic head cancer.  
However, as mentioned before, the role of miR-501-3p in PDAC has not been reported yet. 
We performed in vitro study to verify whether miR-501-3p could promote invasion in PDAC 
cells. In both frequently used cell lines, the invasion rate significantly increased upon the 
up-regulation of miR-501-3p group and remarkably decreased upon down-regulation of 
miR-501-3p group compared with their respective negative control groups. Moreover, 
because miR-501-3p targets cell adhesion molecules as has been reported in the ‘15th 
Annual Conference of Rehabilitation in Multiple Sclerosis’ 
(http://registration.akm.ch/einsicht.php?XNABSTRACT_ID= 
116538&XNSPRACHE_ID=2&XNKONGRESS_ID=126&XNMASKEN_ID=900), we tested 
the well-known epithelial cell-cell adhesion molecular E-Cadherin among different groups to 
further understand the mechanism of increased invasiveness via up-regulation of miR-501-3p. 
The results revealed that up-regulation of miR-501-3p led to a decreased expression of 
E-Cadherin, while down-regulation of miR-501-3p resulted in an increased expression of 
E-Cadherin in both cell lines. E-Cadherin is a transmembrane protein localized at the 
adherens junctions of the epithelial cell basolateral surface and plays a key role in epithelial 
morphology maintenance. Loss of E-Cadherin expression is a well-recognized marker of EMT 
and promotes PDAC progression and invasion (Wong et al., 2003). Our results from in vitro 
study provided evidence for the clinical part that down-regulation of miR-501-3p in pancreatic 
body/tail cancer may lead to a less invasive/metastasis phenotype through up-regulation of 
E-Cadherin.  
In addition, little is known about the molecular targets of miR-501-3p. Although E-Cadherin is 
regulated by miR-501-3p, no database predicts E-Cadherin can be a direct target of 
miR-501-3p because of the unmatched sequence. It indicates that miR-501-3p indirectly 
regulates E-Cadherin expression. Here, we have proven that CDH5 is a direct target gene of 
miR-501-3p. VE-Cadherin, also known as Cadherin-5, is a member of cadherin superfamily, 
expressed by vascular endothelial cells. It appears to be a major adhesive protein involved in 
the control of endothelial cell-cell contact and is of vital important for maintaining endothelial 
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barrier integrity and homoeostasis (Boda-Heggemann et al., 2009). More importantly, 
VE-Cadherin-mediated permeability plays a critical role for carcinogenesis including tumor 
induced angiogenesis and inflammation. It has been demonstrated that tumor cell-secreted 
vascular endothelial growth factor (VEGF) increased endothelial permeability in association 
with decreased VE-Cadherin localization at the plasma membrane (Hu et al., 2006). 
Disruption of VE-Cadherin and subsequently ensuing vascular permeability strongly supports 
tumor metastasis (Liao et al., 2000; Weis et al., 2004). PDAC cell binding can induce focal 
disappearance of VE-Cadherin from endothelial cell junctions and facilitate cancer invasion 
(Nakai et al., 2005). In the present study, we found miR-501-3p directly targeted VE-Cadherin 
and the down-regulation of miR-501-3p led to an increasing VE-Cadherin expression in the 
PDAC cell line Colo357. We hypothesize that down-regulation of miR-501-3p in pancreatic 
body/tail cancer may associate with increased expression of VE-Cadherin, and subsequently 
a better-preserved ‘vascular barrier’ to prevent tumor metastasis.  
However, the function of VE-Cadherin in PDAC is still unclear. VE-Cadherin is traditionally 
been considered restrict in endothelial cells. Using a large database including a consensus 
set of 2984 genes from our previous meta-analysis (Grutzmann et al., 2005), we found that 
CDH5, which encodes VE-Cadherin, could be expressed in both PDAC tissues and cell lines 
(unpublished data). Here, we provided evidence that PDAC cells (Colo357 and Panc89) could 
also express the vascular endothelial specific molecular. Only some of the ‘moderate’ 
malignant PDAC cells expressed the endothelial-marked molecule. Neither the more nor the 
less ‘malignant’ cells expressed VE-Cadherin. The effect of VE-Cadherin on PDAC cells 
needs further research. For this project, the expression of VE-Cadherin in tumor tissues will 
be evaluated in the future because of the small amount of the early stage PDAC tissue 
samples. We are now collecting new samples for immunostaining of VE-Cadherin in tumor 
tissues.  
4.2.4 miR-501-3p reduces proliferation and apoptosis 
Besides invasion, our in vitro study also demonstrated that miR-501-3p might reduce 
proliferation and apoptosis, although the mechanism still needs to be further explored. We 
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found higher caspase-8 expression in Panc-1 cells upon down-regulation of miR-501-3p 
compared to the control, and lower cleaved caspase-8 after up-regulation of miR-501-3p. 
Caspase-8 is engaged in both intrinsic (mitochondria-mediated) pathway and the extrinsic 
(death receptor-mediated) pathway. In the extrinsic pathway, death receptors (e.g. 
Fas/Apo-1/CD95, TRAIL-R1, TRAIL-R2) interact with the corresponding ligants, leading to an 
activation of caspase-8, which could directly activate downstream effector caspases, causing 
apoptosis (Kruidering et al., 2000). In addition, caspase-8 also could cleave Bid to activate 
intrinsic apoptotic pathway (Kruidering et al., 2000). Our results indicate that caspase-8 might 
associate with miR-501-3p-induced decreased apoptosis in PDAC. Moreover, we found that 
miR-501-3p could reduce the expression of death receptors, TRAIL-R1 and TRAIL-R2, and 
consequently lead to more resistance to TRAIL-induced apoptosis. This may be another 
explanation for miR-501-3p-induced decreased apoptosis. To better elucidate the possible 
mechanism of miR-501-3p reduced apoptosis and proliferation, more apoptosis associated 
molecules (e.g. caspase-3, -7, -9, and bcl-2 family) and proliferation associated molecules 
(e.g. Ki-67 and p120) are needed to be studied.  
Our previous study has revealed that TRAIL-R1 and TRAIL-R2 show not only apoptotic 
function but also non-apoptotic functions leading to strong pro-inflammatory responses, which 
are related to survival, proliferation, migration and invasion (Roder et al., 2011). Pancreatic 
cancer cells can produce endogenous TRAIL, which binds to TRAIL-R1 or TRAIL-R2 and 
activate the non-apoptotic pathways to promote tumor progression. 
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5. Summary 
So far, not enough attention has been paid to the diversity between pancreatic head and 
body/tail cancers. Only a few studies have focused on the differences and overall information 
is limited. The current clinical data support higher incidence and easier detection of pancreatic 
head cancer compared with pancreatic body/tail cancer. However, for tumors at the 
local-stage, pancreatic head cancer has a lower survival than pancreatic body/tail cancer. 
Although the previous reports included large cohorts of patients, the evidence is still not so 
convincing because there is a lack of strictly matched cohorts between the two subtypes of 
PDAC. The two groups of patients should be matched not only by tumor stage, but also by 
other well-known prognostic factors such as age, gender, race, tumor markers and 
histological differentiation. 
This study, for the first time, compares pancreatic head cancer and pancreatic body/tail 
cancer using strictly matched early stage PDAC tissue samples by using miRNA expression 
screening. We demonstrate that miR-501-3p and miR-375 are significantly differentially 
expressed between pancreatic head and body/tail cancers, and may contribute to the 
diversity. Furthermore, lower expression of miR-501-3p in pancreatic body/tail cancer is 
associated with a lower tumor recurrence rate after radical surgery therapy compared with 
pancreatic head cancer. miR-501-3p may be regarded as a potential prognostic marker for 
tumor recurrence. A limitation of this clinical part is the relative small study cohort. We have 
collected only 15 pairs of pancreatic head and body/tail cancers during the last 3 years in one 
of the largest Hepatobiliary Pancreatic Surgery Department of P.R. China. Nevertheless, 
considering the relative low incidence of pancreatic body/tail cancer and more importantly, the 
difficulty in strictly matching of age, gender, tumor marker, tumor stage and tumor 
differentiation between the two groups, the study should have good value. Another limitation is 
the small amount of tumor tissues. We are collecting more matched samples for further 
verification and more experiments, such as immunostaining and Western Blot. 
By in vitro studies, we provide first evidence that miR-501-3p is associated with cancer. It can 
promote invasion of PDAC cells, possibly via decreasing the expression of E-Cadherin. This 
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result supports the clinical findings that miR-501-3p is related to tumor recurrence/metastasis. 
Furthermore, other miR-501-3p-induced biological difference of PDAC cells have been found. 
miR-501-3p can decrease apoptosis in PDAC cells and reduce TRAIL sensitivity via 
down-regulation of TRAIL-R1 and -R2. However, the detailed mechanism needs further 
studies.  
Importantly, we demonstrate that E- and VE-Cadherin can be regulated by miR-501-3p, and 
VE-Cadherin is a direct target of miR-501-3p. Although VE-Cadherin was considered as an 
endothelial specific molecular, we prove that PDAC cells can express VE-Cadherin. Yet, the 
specific pathophysiological function of VE-Cadherin in PDAC needs further research. 
In conclusion, we suggest that diversity exists between pancreatic head and body/tail cancers, 
in which the pancreatic body/tail cancer might be ‘less’ malignant than the pancreatic head 
cancer. Lower levels of miR-501-3p might contribute to a less invasive phenotype and 
lower-risk of tumor recurrence/metastasis in pancreatic body/tail cancer than pancreatic head 
cancer with VE-Cadherin as a putative biomarker. These findings confirm the importance of 
subsite division and support the development of individual treatment strategies. 
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7. Supplemental data 
After transfection for 72 hours, Panc-1 cells (source: The First Affiliated Hospital, 
Zhejiang University School of Medicine, Hangzhou, China) were double stained with Annexin 
V-FITC and PI (Sigma, USA). Viable cells are Annexin V-FITC (-) and PI (-). Cells in early 
apoptosis (membrane integrity is present) are Annexin V-FITC (+) and PI (-), while cells in late 
apoptosis (dead) are FITC Annexin V (+) and PI (+). We found that significant more Annexin 
V-FITC (+) and PI (-) cells in the Inhibitor group than its negative control (11.1% vs. 8.7%, P = 
0.010), which indicates that miR-501-3p may reduce PDAC cells early apoptosis 
(Supplemental Figure 1). However, this assay is limited by not distinguishing between cells 
undergoing apoptotic death versus those dying in a necrotic pathway. 
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Supplemental Figure 1. Cell apoptosis/death rate in the Panc-1 cells. (A): Relative apoptosis/death rate 
in PDAC cells transfected with miR-501-3p Mimics and its negative control. (B): Relative 
apoptosis/death rate in PDAC cells transfected with miR-501-3p Inhibitors and its negative control. *: P 
< 0.05. Cell numbers were normalized to the control groups. The experiment was repeated 3 times 
under the same conditions. 
 73
8. Acknowledgements  
 
This is a joint project between Zhejiang University, Hangzhou, PR.China and Kiel University, 
Kiel, Germany. The success of this project means a solid relationship between the two cities 
and two countries. 
First, I want to express my sincere gratitude to my mentor, Prof. Dr rer. nat. Holger Kalthoff for 
his invitation and financial support of my studies at the University of Kiel, for his scientific 
instruction of this research program. I have known him for 5 years since the first meet in 
Hangzhou, China, 2007. We have established a great relationship and kept close cooperation 
during the past 5 years. I am sure that we can successfully win a joint project in the near 
future. In addition, I would like to thank him for the enthusiastic help in general aspects of my 
living in Kiel. No suitable words can be cited to express my acknowledgment. 
Special thanks should be given to Dr. rer. nat. Trauzold for her great support throughout this 
study and her help in this research program, particularly for her very scientific guidance of this 
study, intensive discussion at this manuscript.  
Many thanks to Charlotte Hauser, Karen Legler, Hendrik Fritsche,  Sebastian Hübner and 
Gökhan Alp, they gave me a lot of help in my working and living in Kiel. 
Many thanks to my Chinese colleagues (Prof. Shusen Zheng, Prof. Xiao Xu, Zhikun Liu, 
Xuyong Wei), who give me the financial and technical supports in the joint project.  
Many thanks to the SHANGHAI BIOTECHNOLOGY CORPERATION who helps me complete 
the miRNA microarray and PCR verification analyses.  
Finally, I should sincerely thank my wife Panpan Ye, my parents and my colleagues in 
Hangzhou for their huge support during my research project in Kiel. All colleagues of mine 
gave me a lot of support for my study and living in Kiel. This is grateful acknowledged. 
 74
9. Curriculum vitae 
Surname:            Ling 
Name:             Qi 
Sex:             Male 
Date of birth:           July 23, 1982    
Plate of birth:           Huzhou, Zhejiang, People’s Republic of China 
Nationality:               China 
Correspondence Address:  
                  Division of Hepato-biliary-Pancreatic Surgery 
Department of Surgery 
                               First Affiliated Hospital 
                               Zhejiang University School of Medicine 
                               310003, Hangzhou 
                               People’s Republic of China 
Current Position: 
                               Fellow surgeon  
Telephone:                     
86-38-1919-5520 (mobile)      
                               86-571-87236567 (office) 
E-mail:               
lingqi@zju.edu.cn; or lingqilynch@163.com  
Education: 
2000–2005     
              School of Medicine, Zhejiang University     Medical Bachelor     
2005–2007    
              School of Medicine, Zhejiang University     Medical Master     
2010–2013    
              School of Medicine, Zhejiang University     Medical Doctor  
Professional Experience: 
 75
2007-2010  Department of Surgery 
                       First Affiliated Hospital 
Zhejiang University, School of Medicine 
      Resident  
2010-date    Department of Surgery 
                       First Affiliated Hospital 
Zhejiang University, School of Medicine 
      Fellow 
2012-2012 Institute for Experimental Cancer Research 
Comprehensive Cancer Center North  
University of Kiel 
                       Visiting scholar 
 
Job Experience: 
                      Over 400 operation performed pre year 
                      Experience in the surgical treatment of following disease: 
                      Hepatocellular carcinoma 
                      Liver cirrhosis 
                      Pancreatic ductal adenocarcinoma  
               
Research Interests: 
           Molecular diagnosis and treatment of pancreatic ductal adenocarcinoma 
 Prediction of the post-operative complications in liver transplantation 
           Series management of HBV-related liver diseases:  
(Fibrosis-Cirrhosis- Hepatocellular carcinoma) 
 
Publications in the past five years (as the first two authors):   
 76
1. Ling Q, Xie HY, Lu D, Wei XY, Gao F, Zhou L, Xu X, Zheng SS. Association between 
donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes 
mellitus after liver transplantation in a Han Chinese population. Journal of Hepatology, 
Available online 4 October 2012  
2. Ling Q, Xu X, Wei Q, Liu X, Guo H, Zhuang L, Chen J, Xia Q, Xie H, Wu J, Zheng S, Li J. 
Downgrading MELD improves the outcomes after liver transplantation in patients with 
acute-on-chronic hepatitis B liver failure. PLoS One 2012, 7(1):e30322. 
3. Ling Q, Xu X, Wei X, Wang W, Zhou B, Wang B, Zheng S. Oxymatrine induces human 
pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP 
families, and releasing of cytochrome c. Journal of Experimental & Clinical Cancer 
Research 2011, 2011 Jun 29;30:66. 
4. Ling Q, Xu X, Wei Q, Wei X, Wang Z, Zhou L, Zheng S. Impact of preexisting diabetes 
mellitus on outcome after liver transplantation in patients with hepatitis B virus-related 
liver disease. Dig Dis Sci. 2011 Mar;56(3):889-93. 
5. Ling Q, Xu X, Li J, Wu J, Chen J, Xie H, Zheng S. A new serum cystatin C-based equation 
for assessing glomerular filtration rate in liver transplantation. Clin Chem Lab Med. 
2008;46(3):405-10.  
6. Ling Q, Xu X, Li JJ, Chen J, Shen JW, Zheng SS. Alternative definition of acute kidney 
injury following liver transplantation: based on serum creatinine and cystatin C levels. 
Transplant Proc. 2007 Dec;39(10):3257-60.  
7. Xu X, Ling Q, Zhang M, Gao F, He Z, You J, Zheng S. Outcome of patients with 
hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. 
Transplantation. 2009 May 27;87(10):1514-9. (co-first author) 
8. Xu X, Ling Q, Wei Q, Wang K, Zhou B, Zhuang L, Zhou L, Zheng S. Korean red ginseng: 
a new approach for the treatment of graft-versus-host disease after liver transplantation. 
Transplant Proc. 2011 Sep;43(7):2651-5. 
9. Xu X, Ling Q, Wei Q, Wu J, Gao F, He ZL, Zhou L, Zheng SS. An effective model for 
predicting acute kidney injury after liver transplantation. Hepatobiliary Pancreat Dis Int. 
2010 Jun;9(3):259-63.  
 77
10. Xu X, Ling Q, Gao F, He ZL, Xie HY, Zheng SS. Hepatoprotective effects of marine and 
kuhuang in liver transplant recipients. Am J Chin Med. 2009;37(1):27-34.  
11. Wu YJ, Ling Q, Zhou XH, Wang Y, Xie HY, Yu JR, Zheng SS. Urinary trypsin inhibitor 
attenuates hepatic ischemia-reperfusion injury by reducing nuclear factor-kappa B 
activation. Hepatobiliary Pancreat Dis Int. 2009 Feb;8(1):53-8.  
12. Xu X, Ling Q, He ZL, Gao F, Zheng SS. Post-transplant diabetes mellitus in liver 
transplantation: Hangzhou experience. Hepatobiliary Pancreat Dis Int. 2008 
Oct;7(5):465-70. 
13. Xu X, Ling Q, Wu J, Chen J, Gao F, Feng XN, Zheng SS. A novel prognostic model based 
on serum levels of total bilirubin and creatinine early after liver transplantation. Liver Int. 
2007 Aug;27(6):816-24.  
Awards 
1. 2000, First-class Scholarship and awards for graduate of Zhejiang province 
2. 2009, First-class award for development in science and technique of Zhejiang province  
3. 2009, First-class award for development in medical science of Zhejiang province  
4. 2011, First-class award for development in medical science of Zhejiang province  
 
 
